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!3. Abstract 
 
Background 
Diabetes mellitus (DM) is a group of metabolic diseases characterized by chronic 
hyperglycemia. Type 1 diabetes mellitus (T1DM) is one of the most common 
endocrine and metabolic conditions in childhood, rapidly increasing in incidence and 
associated with increased long-term morbidity and mortality. Optimal diabetes 
management to avoid or delay the long-term complications of diabetes is important. 
Diabetes education remains a cornerstone in this work, in addition to optimal diabetes 
treatment, glycemic control and avoidance of the short-term complications of diabetes 
while screening for complications and the associated comorbidities. 
Aims 
The aim of this thesis is a comparative study of Norway and Canada, focusing on the 
choice of target of glycemic control and insulin regimen in treatment of T1DM in 
children. 
Methods 
This thesis consists of two parts; Part one is a literature review on T1DM based upon 
a non-systematic search in PubMed. Part two is the clinical part of our thesis. We 
made an electronic questionnaire based on international guidelines and performed a 
combined survey and interviews in addition to our clinical experiences visiting 
hospitals in Norway (Oslo University Hospital (OUS)) and Canada (British Columbia 
Childrens’s Hospital (BCCH) and Hospital for Sick Children (SickKids)). 
Results 
Performing our comparative study of Norway and Canada we found that management 
of childhood T1DM had many similarities in terms of diabetes management, e.g. 
diabetes education and composition of the multidisciplinary team. Some differences 
between the nations and hospitals exist in guidelines, management at the time of 
diagnosis, hospital admittance, frequency of follow up, choice of insulin regimen and 
target of glycemic control. While every child diagnosed with T1DM at OUS is 
offered to start with an insulin pump at diagnosis, all the children at SickKids are 
started on insulin injection therapy. The two Canadian hospitals both preferred to wait 
with pump therapy. Approximately two thirds of the Canadian patients were on 
conventional regimens, compared to almost none at OUS.  Both Canadian Hospitals 
had age-adjusted HbA1c targets that were higher than OUS for the children less than 
12 years of age.   
Conclusion 
Optimal diabetes management to avoid short- and long-term complications is 
important. Children with T1DM should, where possible, receive the best diabetes care 
available. The hospitals we visited in Norway and Canada all had well-organized 
diabetes care, mostly according to international guidelines of pediatric diabetes. Tight 
glycemic control and intensive insulin regimen has been shown to reduce and delay 
the diabetes late complications and should be included as part of the management of 
childhood diabetes. 
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!4. Aims and methods 
 
4.1. Aims 
 
Our student thesis is part of a larger study with six fellow medical students; “Diabetes 
in children; a global, comparative study”. The aim of this study is a survey of how 
children with diabetes are diagnosed, treated and followed up throughout the world 
based upon clinical experiences and by carrying out combined surveys and 
interviews. Our group of students has travelled to various countries in the world 
including the United States, Australia, Canada, Rwanda and India. We aim at 
identifying the national, regional or local modifications to international guidelines of 
pediatric diabetes that are made throughout the world. We also wanted to focus upon 
challenges, obstacles and restrains in the various countries visited and the ways they 
are met.  
 
The aim of this thesis was a comparative study between Norway and Canada. We 
focus primarily on T1DM, as this is the most common type of diabetes in children, 
especially in the western world. We have concentrated on the choice of target of 
glycemic control and insulin regimen in treatment of diabetes in Canada and Norway, 
the influence of hypoglycemia and the importance of diabetes education, diabetes 
multidisciplinary teams and the follow-up with regard to these themes. 
 
. 
4.2. Methods 
 
This student thesis consists of two parts; Part one is a literature review on T1DM and 
part two is the clinical survey. Most of our sources of information derive from a non-
systematic search in PubMed and from the International Society for Pediatric and 
Adolescent Diabetes (ISPAD) guidelines references.  
 
Performing a global, comparative study, all the students that are part of our larger 
study decided to do a combined survey and interviews in addition to our clinical 
experiences. Travelling to different parts of the world, we have used the same 
questionnaire so that our data will be more easily comparable.   
 
During the spring of 2009 we made an electronic questionnaire (appendix 1) based on 
the 2009 ISPAD and American Diabetes Association (ADA) guidelines together with 
four of our fellow students at the University of Oslo; Lene Sleire, Martine Aurora 
Munkvold, Lise Haldorsen Willumsen and Idun Stenhammer Aanerød. This work was 
done with the help of prof. Borghild Roald and senior consultant Torild Skrivarhaug, 
who evaluated and gave us feedback on our questionnaire and diabetes nurse Siv 
Janne Kummernes at the OUS, pediatric department who gave an interview and 
helped us adjust our questionnaire. The questionnaire was our tool in the 
semistructured interviews of health workers in Norway and Canada to gather 
information on T1DM in children and adolescents.  It consists of two parts; the first 
part concerns information regarding incidence, prevalence, mortality, national health, 
patient organizations, registers and complications in the state/country we were 
studying. The second part focuses on the single hospitals/departments, e.g. 
7
!hospitalizations, diagnostics, treatment and follow up, treatment goals and quality of 
life and mental health. 
 
Part two of our thesis is based upon our experiences and the information we gathered 
interviewing health workers during our visits to three different hospitals in Norway 
and Canada during the time between May and July 2010. We visited OUS, Ullevål in 
Oslo, Norway. In Canada we visited BCCH in Vancouver, British Columbia and 
SickKids in Toronto, Ontario. At OUS we interviewed diabetes nurse Kummernes, 
attended diabetes clinics and sat in with our supervisor Dr. Torild Skrivarhaug at her 
clinics. At BCCH we interviewed Dr. Daniel Metzger and sat in with different 
members of the diabetes team at the diabetes clinic. We also visited a primary health 
care center specializing in diabetes management and education in Vancouver. At 
SickKids we interviewed Dr. Denis Daneman and different members of the diabetes 
team at the diabetes clinic.  
 
The questionnaire was sent to the interview subjects via e-mail in advance of the 
interview. The interviews were tape recorded, and transcribed shortly after the 
interviews. The information gathered from these interviews contains no sensitive 
patient information. Parts of the information we gathered to complete the 
questionnaire was found in literature and from the Internet. 
 
 
5. PART ONE  
- Literature review on T1DM in children and adolescents 
 
5.1. Introduction- diabetes mellitus 
 
DM is a group of metabolic diseases characterized by chronic hyperglycemia 
resulting from defects in insulin secretion, insulin action or both (1).  T1DM is one of 
the most common endocrine and metabolic conditions in childhood and is rapidly 
increasing in many countries, especially amongst the youngest children. In 2010, the 
total child population of the world (0 – 14 years) was estimated to be 1.9 billion, of 
whom 0.025% has diabetes. This means that approximately 480,000 children around 
the world have diabetes with 75,800 new cases diagnosed each year and an annual 
increase in 3,0% (2). 
 
Insulin treatment is life-saving and lifelong. Self-discipline and adherence to a 
balanced diet is necessary to manage T1DM. In many countries, especially in less 
privileged families, access to self-care tools and insulin is limited. This may lead to 
severe handicap and early death in patients with T1DM.  
 
From a global perspective, lack of insulin is the most common cause of death in a 
child with T1DM. Many children die before their diabetes is diagnosed (3). 
Establishing an international collaboration to decrease morbidity and mortality in 
children with T1DM is important. The International Diabetes Federation (IDF) "Life 
for a Child" program was established in 2001 with support from the Australian 
Diabetes Council and the international charity HOPE worldwide. “Life for a child” is 
a support program in collaboration with ISPAD and other organizations in which 
8
!individuals, families and organizations contribute to help children with diabetes in 
developing countries (4).  
 
The ISPAD guidelines 2009 places diabetes education at the center of clinical 
management; “Education is the vehicle for optimal self-management, the key to 
success” (2). 
 
 
5.1.1. History 
 
T1DM was once a fatal disease. After the onset of clinical symptoms patients would 
usually die within a year or two. The discovery of insulin at the University of 
Toronto, Canada in 1922 revolutionized the treatment and prognosis of the disease. 
Dr. Frederick Banting and biochemist J.J.R. Macleod, both Canadians, were in 1923 
awarded the Nobel Prize in Medicine for the discovery of insulin. Dr. Banting shared 
his prize with his laboratory assistant, Charles Best, and MacLeod shared his with 
biochemist James Collip. The patent for insulin was sold to the University of Toronto 
for one half Canadian dollar (5). 
 
Before the age of genetics, the only insulin available was 
purified animal-sourced insulin, mostly made from pigs or 
cattle. The amino-acid structure of insulin was discovered in 
the 1950’s, and in the early 1960’s the first synthetic insulin 
was produced. In 1977 Herbert Boyer made the first 
genetically-engineered synthetic “human” insulin, using E.coli. 
Boyer and Eli Lilly and Company offered the first 
commercially available human insulin – Humulin on the 
market. Today most insulin used still are recombinant human 
insulin or its analogues (6). 
 
Canada was the country in which insulin was first used to   
treat diabetes and the country still has high ambitions on   Fig. 1. The Flame of 
behalf of diabetes treatment. Researchers are working to  Hope, London,  
improve the quality of life for people with diabetes, as well  Ontario (36) 
as working to find a cure for the disease. The Flame of Hope  
(front page and Fig.1) is a flame that was lit at Sir Fredrick  
Banting Square in London, Ontario in1989 as a tribute to Dr. Banting and all the 
people that have lost their lives to diabetes. The flame will remain lit until there is a 
cure for diabetes (7). 
      
 
 
5.1.2. Classification of DM 
 
DM is traditionally classified into two main types; T1DM and type 2 diabetes mellitus 
(T2DM). Some other subtypes exist. The ADA and an expert committee from the 
World Health Organization (WHO) recommend an etiological taxonomy on the 
classification and diagnosis of diabetes (1): 
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!Etiological classification of disorders of glycemia 
 
I. Type 1 diabetes mellitus (T1DM) 
! -cell destruction, usually leading to absolute insulin deficiency  
A. Immune mediated  
B. Idiopathic 
 
II. Type 2 diabetes mellitus  (T2DM) 
May range from predominantly insulin resistance with relative insulin deficiency to a 
predominantly secretory defect with or without insulin resistance 
 
III. Other specific types 
A. Genetic defects of ! -cell function  
B. Genetic defects in insulin action 
C. Diseases of the exocrine pancreas 
D. Endocrinopathies 
E. Drug- or chemical-induced 
F. Infections 
G. Uncommon forms of immune-mediated diabetes 
H. Other genetic syndromes sometimes associated with diabetes 
 
IV. Gestational diabetes 
Table 1. Etiological classification of disorders of glycemia (1) 
 
Classifying DM into T1DM, T2DM and monogenic diabetes has important 
implications for both therapeutic decisions and educational approaches, even though 
the child presenting with severe fasting hyperglycemia will require insulin therapy 
regardless of the type. In most western countries T1DM accounts for more than 90% 
of childhood and adolescent diabetes, but T2DM is becoming more common and 
accounts for a significant proportion of DM in certain at risk populations (8). The 
possibility of other types of diabetes should be considered when suspected, e.g. with 
an autosomal dominant family history of diabetes, associated conditions or syndromic 
features in the child or a history of exposure to drugs known to be toxic to beta cells 
or cause insulin resistance. Characteristic features of T1DM in comparison with 
T2DM and monogenic diabetes in children and adolescents are shown in table 2 (1).  
 
 
Table 2. Clinical characteristics of type 1 diabetes mellitus (T1DM),  type 2 diabetes mellitus (T2DM)  
and monogenic diabetes mellitus (DM) in children and adolescents (1) 
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!5.1.3. Etiology and pathogenesis 
 
T1DM has a prodromal phase in with a progressive loss of insulin-producing beta-
cells in the Langerhans islets in the pancreas. By the time of diagnosis, only 10-20 % 
of insulin-producing beta-cells are still functioning (9). In most cases T1DM has an 
autoimmune pathogenesis with autoantibodies to glutamic acid decarboxylase (GAD), 
islet cell autoantibodies (ICAs) and/or insulin autoantibodies (IAAs).  These 
serological markers of an underlying autoimmune process can be found circulating in 
the blood at the time of diagnosis in 85-90 % of patients (9).  
 
Several theories have been proposed on the etiology and pathogenesis of DM. 
Eisenbarth proposed our current model for T1DM, subtype A in the 1980s. This 
theory claims that we are all born with a certain degree of genetic susceptibility for 
T1DM, decided in our Human Leukocyte Antigen (HLA) genotypes DR and DQ and 
to a lesser extent in a host of other genetic loci called insulin-dependent diabetes 
mellitus (IDDM) susceptibility genes. HLA locus counts for about 50 % of the 
genetic susceptibility (10). 
 
Genetic susceptibility is not enough for developing T1DM. In monozygotic twins 
where one of the twins has T1DM, the other twin will develop the disease only in 
about 36% (10). Contributing factors to developing T1DM has been hypothesized, but 
not verified (1, 10, 11): 
• Viruses (enteroviruses, coxsackie, congenital rubella) 
• Environmental toxins (nitrosamines) 
• Foods (gluten, cereals, early exposure to cow’s milk proteins) 
• Vitamin D deficiency 
• Perinatal factors ( maternal age, preeclampsia and neonatal jaundice) 
 
 
5.1.4. Epidemiology  
 
5.1.4.1. World epidemiology 
 
Many countries in the world keep records of the incidence of T1DM. The 
International Diabetes Federation (IDF) collects data on diabetes worldwide and 
published its first Diabetes Atlas in 2000 showing the incidence of T1DM around the 
world (12). 
 
Two international collaborative projects; the Diabetes Mondiale study (DiaMond) and 
the Europe and Diabetes study (EURODIAB) began monitoring trends in incidence in 
the 1980s.  The data has been collected through the establishment of population- 
based regional or national registries using standardized definitions, data collection 
forms and methods for validation (3). 
 
The incidence of T1DM varies greatly between different countries, within countries 
and between different ethnic populations. Finland and Sardinia are among the 
countries with the highest incidences (37 to 57,6 per 100 000 children 0-14 years of 
age). Venezuela and parts of China have the lowest incidence (0,1 to 0,5 per 100 000) 
(11,12). Countries with high latitudes tend to have a higher incidence (11). An annual 
11
!increase in the incidence of T1DM by 2-5 % each year is reported in Europe, The 
Middle East and Australia (11). There is also a tendency of a more steep increase in 
some of the low prevalence countries in Central and Eastern Europe (3).  
 
 
 
Fig. 2. New cases of type 1 diabetes mellitus (T1DM)  in children 2010 (13). 
 
 
5.1.4.2. Norway 
 
The incidence of T1DM in children 0-14 years of age in Norway is about 36 per 
100 000 per year (14). Norway has also witnessed an increasing incidence, about 1-3 
% every year, with the greatest increase in the age group 10-14 years of age (15). In 
2009, 335 new cases of T1DM in children 0-15 years were reported to the Norwegian 
Childhood Diabetes Registry (NCDR).  More than 95 % of cases in this age group 
had T1DM (14). In the EURODIAB study, Norway had the fifth highest incidence 
rate (1989-1998) in Europe (16).  
 
5.1.4.3. Canada 
 
In 2010 Canada had an incidence of about 22 per 100 000 per year of T1DM in 
children 0-14 years of age (17). This is the sixth highest incidence rate of T1DM in 
children 0-14 years of age in the world. The incidence rate is rising 3-5 % in Canada, 
with the greatest increase in the age group 5-9 years (17).  The incidence of T1DM 
varies within Canada.  Two areas – the Prince Edwards Islands at the west coast and 
Newfoundland have an incidence of more than 40 per 100 000 per year of T1DM. 
Different ethnic groups has different incidence of T1DM (18).  
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!5.1.5. Clinical guidelines 
 
The way health professionals care for children with T1DM can vary between different 
regions within one country as well as between different countries. T1DM is a lifelong 
disease associated with increased morbidity and reduced quality of life, especially in 
individuals with late complications. It is considered important to optimize diabetes 
care in order to prevent or delay the development of late complications. 
Implementation of guidelines to help optimize diabetes care will benefit the individual 
patient and his or her family as well as the health care system and the society. Late 
complications of diabetes lead to increased costs for both the patient and the society 
and the cost-benefit of interventions to improve diabetes care has been well 
established by several studies (19). The IDF has published a “Guide for Guidelines” 
as a help to establish realistic guidelines in their country or organization.  
 
5.1.5.1. International Society for Pediatric and Adolescent 
Diabetes (ISPAD) 
 
ISPAD was established in 1974 and presents itself as a professional international 
organization whose aims are to promote clinical and basic research, education and 
advocacy in childhood and adolescent diabetes. The strength of ISPAD lies in the 
scientific and clinical expertise of its members. ISPAD is the only international 
society focusing specifically on all types of childhood diabetes and publishes the 
journal Pediatric Diabetes (12).  
In 1993 ISPAD formulated the Declaration of Kos, intended to proclaim their 
commitment to “promote optimal health, social welfare and quality of life for all 
children with diabetes around the world by the year 2000”.  The first set of ISPAD 
consensus guidelines was published in 1995, the second set in 2000. These guidelines 
have contributed to increased knowledge of childhood and adolescent diabetes 
worldwide. The ISPAD guidelines have been translated into 11 different languages. 
The current edition, the ISPAD Clinical Practice Consensus Guidelines 2009 
Compendium, was published in 2009 (2).  Norway adheres to the ISPAD Guidelines 
for childhood and adolescent diabetes. 
 
5.1.5.2. Canadian Diabetes Association (CDA) 
 
The CDA was founded in 1953 and is active in more than 150 Canadian communities. 
CDAs slogan says; “We're leading the fight against diabetes by helping people with 
diabetes live healthy lives while working to find a cure”. In 2008 CDA published the 
Canadian Diabetes Association 2008 Clinical Practice Guidelines (CDA CPG) for 
the Prevention and Management of Diabetes in Canada (20). These current 
guidelines are for the most part aimed at the adult diabetic population, but they 
include two chapters on T1DM and T2DM in children and adolescents.  
 
These guidelines recognize that the most effective treatment is not necessarily the 
most cost-effective ones when it comes to social economics (20). 
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!5.1.6. Diagnostic criteria  
 
Symptoms of diabetes are often the classical triade of polyuria, polydipsia and 
unexplained weight loss (1, 20).  
 
 
Fig.3. The warning signs of diabetes (21). 
 
The diagnosis of T1DM is based on measurements of blood glucose and clinical 
symptoms. 
 
ISPAD and CDA criteria for the diagnosis of diabetes mellitus. 
1. Symptoms of diabetes plus casual plasma glucose concentration "11.1 mmol/L OR 
2. Fasting plasma glucose (FPG) "7.0 mmol/l OR 
3. 2-hour postload glucose "11.1 mmol/l during an oral glucose tolerance test (OGTT) 
 
Table 3. International Society for Pediatric and Adolescent Diabetes (ISPAD) and Canadian Diabeets 
Association (CDA) criteria for the diagnosis of diabetes mellitus. Casual is defined as any time of day 
without regard to time since last meal. Fasting is defined as no caloric intake for at least 8 hours (1,20).  
 
 
5.1.7. Education and multidisciplinary team 
 
5.1.7.1. Education 
 
Both the ISPAD guidelines and the CDA CPG emphasize the importance of a 
multidisciplinary pediatric diabetes healthcare team in the education of children with 
newly diagnosed T1DM and their families. ”Education is the keystone of diabetes 
care and structured self-management education is the key to a successful outcome” 
(22). 
 
The CDA CPG states that education topics should include: 
• Insulin action, administration and dosage adjustment 
• Blood glucose (BG) and ketone testing 
• Sick-day management 
• Prevention of diabetic ketoacidosis (DKA) 
• Nutritional therapy 
• Exercise 
• Prevention, detection, and treatment of hypoglycemia  
14
!Extra attention should be given special events such as school entry, high school entry 
etc. (20). 
 
ISPAD suggestions include dividing education into primary and secondary levels with 
basic survival skills at diagnosis, and a continuing curriculum as the child grows older 
and time goes by: 
 
Primary (level 1) education 
At diagnosis: Survival skills 
1. Explanation of how the diagnosis has been made and reasons for symptoms 
2. Simple explanation of the uncertain cause of diabetes. No cause for blame 
3. The need for immediate insulin and how it will work 
4. What is glucose? - normal BG levels and glucose targets 
5. Practical skills - insulin injections - blood and/or urine testing and reasons for monitoring 
6. Basic dietetic advice 
7. Simple explanation of hypoglycemia 
8. Diabetes during illnesses. Advice not to omit insulin—prevent DKA 
9. Diabetes at home or at school including the effects of exercise 
10. Identity cards, necklets, bracelets and other equipment 
11. Membership of a Diabetes Association and other available support services 
12. Psychological adjustment to the diagnosis 
13. Details of emergency telephone contacts. 
 
Secondary (level 2) education 
Continuing educational curriculum 
1. Pathophysiology, epidemiology, classification and metabolism 
2. Insulin secretion, action and physiology 
3. Insulin injections, types, absorption, action profiles, variability and adjustments 
4. Nutrition—food plans; qualitative and quantitative advice on intake of carbohydrate, fat, proteins 
and fiber; coping with special events and eating out; growth and weight gain; ‘‘diabetic foods’’; 
sweeteners and drinks 
5. Monitoring, including glycated hemoglobin and clear (agreed) targets of control 
6. Hypoglycemia and its prevention, recognition and management including glucagon 
7. Intercurrent illness, hyperglycemia, ketosis and prevention of ketoacidosis 
8. Problem solving and adjustments to treatment 
9. Goal setting 
10. Micro and macro-vascular complications and their prevention. The need for regular assessment 
11. Exercise, holiday planning and travel, including educational holidays and camps 
12. Smoking, alcohol and drugs 
13. School, college, employment and driving vehicles 
14. Sexuality, contraception, pregnancy and childbirth 
15. Updates on research. 
Table 4. International Society for Pediatric and Adolescent Diabetes (ISPAD) recommendations on 
organization of diabetes education (22) 
 
Different ways of making diabetes knowledge more accessible for the children with 
diabetes and their caregivers can be: 
• Distribution of written material i.e. written guidelines and booklets 
• Using an appropriate language 
• Using multimedia tools e.g. videos, CDs and computer games 
• Attending diabetes camps, where the children and families can increase their 
knowledge about diabetes and meet with other children with diabetes and 
families that are in the same situation. 
 
ISPAD Guidelines emphasize some universal principles for diabetes education. It 
characteristics should be (22):  
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!• Easily accessible 
• Delivered by healthcare professionals who have an understanding of the 
special and changing needs of young people as they go through different 
stages of life, 
• Adaptable and personalized, 
• Based on thorough assessment of the person’s attitudes, beliefs, learning style, 
ability and readiness to learn, existing knowledge and goals. 
• Educators should have access to continuing specialized training in diabetes 
education and educational methods, 
• Part of a continuous process and repeated for it to be effective. 
 
 
5.1.7.2. Diabetes multidisciplinary team 
 
Dr. Elliot Joslin (1869-1962) was the first American diabetes specialist. He was a 
pioneer in the field of teaching patients to care for their own disease, a concept now 
known as diabetes self-management education (DSME). Dr. Joslin thought it 
important to have multiple health care professionals participating in the treatment of 
people with diabetes and he began developing the concept of the diabetes team. He is 
accredited of having said: “the diabetic who knows the most lives the longest” (23).  
 
A multidisciplinary team providing diabetes care should as a minimum consist of a 
diabetes specialist nurse and a dietician. ISPAD recommend that it consists of: 
• Pediatrician specializing in diabetes or endocrinology (or physician with a 
special interest in childhood and adolescent diabetes) 
• Diabetes nurse specialist or diabetes nurse educator 
• Dietitian (or nutritionist) 
• Pediatric social worker with training in childhood diabetes and chronic illness 
and/or psychologist trained in pediatrics and with knowledge of childhood 
diabetes and chronic illness 
• The family and child should be recognized as part of the team 
It is recognized that in geographical areas with a low population density and few 
cases of childhood diabetes, it might be difficult to assemble a complete 
multidisciplinary team. ISPAD recommend that in cases like these, care should be 
provided by a locally based pediatrician or physician who can lean on regional centers 
with more facilities and resources (24).  
 
5.1.8. Treatment of diabetes 
 
Children with T1DM require administration of exogenous insulin because of the 
destruction of their pancreatic islet cells and lack of endogenous insulin production. 
During the first few weeks after diagnosis the endogenous insulin secretion may 
recover for a short period of time. This is often referred to as the “honeymoon period” 
and calls for tightly controlled BG and often a reduction or even full stop in the 
insulin administration (25). Nutrition is an important aspect of the diabetes 
management and consists of meal planning, carbohydrate counting and understanding 
how meals affect the BG. 
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5.1.8.1. Insulin treatment 
 
Insulin was first used as treatment of T1DM in 1922 (26). The physiologic secretion 
of insulin in a non-diabetic individual is difficult to mimic accurately. A non-diabetic 
has a constant basal secretion of insulin with bursts of insulin secretion, e.g. after 
meals. With the introduction of several new insulin preparations since 1996, insulin 
therapy options for diabetics have expanded.  Insulin therapies can now more closely 
mimic physiologic insulin secretion and thus achieve better glycemic control in 
patients with diabetes (27). Insulin is administered either subcutaneously or 
intravenously. 
 
5.1.8.1.1. Insulin preparations 
 
The types of insulin can be classified by their onset, peak and duration of action (25): 
 
 
Fig.4. Comparison between different insulin types and their profile (29) 
 
• Rapid-acting and short-acting insulin types: 
o Typically administered as a pre meal bolus based on the carbohydrate 
content of food and the BG level.  
o Provide basal insulin levels when delivered by continuous 
subcutaneous infusion via an insulin pump. 
o Commonly used preparations: 
! Rapid-acting analogues: Insulin lispro (Humalog®), Insulin 
aspart (Novolog®, Novorapid®). 
! Short-acting analogues: Human regular insulin (Humulin®S), 
soluble insulin. 
 
• Intermediate-acting insulin:  
o Usually given two or three times a day. 
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!o May be given in combination with long-acting insulins. 
o Provides some coverage for meals e.g., NPH (Neutral Protamine 
Hagedorn) insulin given before breakfast will cover lunch. 
o Commonly used preparations: Isophane (NPH®), Lente (Humulin®N) 
 
• Long-acting insulin: 
o Given once or twice a day.  
o Provide a basal insulin level that suppresses hepatic glucose production 
and maintains near-normal glucose levels in the fasting state.  
o Commonly used preparations: 
! Long-acting: Ultralente (Humulin ®U) 
! Very long-acting: Detemir (Levemir®), Glargine (Lantus®) 
 
 
5.1.8.1.2. Insulin administration 
 
Insulin can be administered by syringe, pen or pump (25): 
 
• Needle and syringe 
o An advantage of needle and syringe is that NPH and short- or rapid-
acting insulins can be mixed in a single injection, thereby reducing the 
number of injections.  
 
• Pen 
o Pens are supplied pre-filled with insulin and may be either disposable 
or reusable.  
o The ease of use and portability of pens are appealing to many patients.  
 
• Insulin pump (continuous subcutaneous insulin infusion (CSII)) 
o Insulin pump therapy is at present the best way to imitate the 
physiological insulin profile (10). 
o Rapid- or short-acting insulin is infused through a subcutaneously 
inserted catheter. 
o The insulin is delivered at set intervals to provide a pre-programmed 
basal-rate. 
o Boluses of insulin are added to counterbalance postprandial rise in BG 
and to correct out-of-range BG levels. 
o Information on insulin administration, frequency of catheter site 
changes, and frequency and timing of pre-meal insulin boluses can be 
downloaded from a memory chip within the pump. This is very helpful 
for guidance of glycemic control, both for the patient at home and at 
follow-ups.  
o Insulin pump therapy relies on frequent blood glucose monitoring and 
appropriate adjustment of insulin infusion rates. 
o Insulin pumps have not yet incorporated a "closed loop" system in 
which blood glucose values are determined and automatically used to 
reprogram the insulin pump. 
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5.1.8.1.3. Insulin regimens 
 
There are multiple insulin regimens with variations in insulin preparations, 
administrations and number of insulin injections throughout the day.  
 
• Conventional regimens  
o Usually “two injections daily” or “three injections daily” with 
administration of an intermediate-acting insulin (NPH) at least twice a 
day and with a rapid- or short-acting insulin two or three times a day 
(30). 
o The patient and family must adjust their lifestyle so that meals and 
exercise occur on a relatively fixed daily schedule, as the regimens are 
fixed. 
 
• Intensive regimens 
o Insulin administrations that aim at mimicking the physiologic insulin 
secretion more closely by maintaining a basal insulin level and add 
additional pre-meal and pre-snack boluses of rapid- or short-acting 
insulin to minimize postprandial elevation of BG.  
o The boluses are adjusted according to the carbohydrate content of 
meals as well as the current BG level and expected level of exercise 
after the meal. 
o Allows more flexibility in terms of timing and carbohydrate content of 
meals compared to the conventional regimens, but demands increased 
involvement of the patients and families. Without proper education, 
increased BG monitoring, increased frequency of insulin 
administration, carbohydrate counting and judging of the impact of 
physical activity on insulin requirements, the benefits of following an 
intensive regimen might not be attained (25). 
o The choice of intensive regimen delivered either by multiple daily 
injections (MDI) or by CSII, is based upon patient, family, and 
clinician preferences (25). 
o Demonstrated by controlled studies (e.g. the Diabetes Control and 
Complications Trial (DCCT)) to achieve better glycemic control and 
reduce the incidence of long-term sequelae in adults and adolescents 
compared to conventional insulin therapy (10, 25, 31). 
o Reported by observational studies to be a safe, effective and superior 
alternative to conventional regimens with improved glycemic control 
in children (32, 33). 
o Is recommended that to be selected whenever possible (25). 
 
 
5.1.8.1.4. Choice of insulin regimen – multiple daily 
injections (MDI) versus continuous subcutaneous 
insulin infusion (CSII) 
 
A systematic review comparing CSII versus MDI for T1DM was published in The 
Cochrane Library in 2010. The review looked at 23 studies that had randomized 976 
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!participants with T1DM to either intervention. The main results were (34): 
• There was a statistically significant difference in glycated hemoglobin (HbA1c) 
favoring CSII. 
• There were no obvious differences between the interventions for non-severe 
hypoglycemia, but severe hypoglycemia appeared to be reduced in those using 
CSII.  
• Quality of life measures suggest that CSII is preferred over MDI.  
• No significant difference was found for weight.  
• There was insufficient evidence regarding adverse events, mortality, morbidity 
and costs. 
 
Observational studies have reported improved glycemic control and fewer episodes of 
hypoglycemia with CSII compared with previous insulin regimens, both conventional 
and MDI therapy, in children and adults. Beneficial use of insulin pump therapy has 
been reported in children as young as two years of age. On the other side, several 
small controlled trials comparing CSII to MDI have shown no difference in glycemic 
control and frequency of hypoglycemic episodes in children. The following reports 
describe some of the beneficial effects of insulin pump therapy (25): 
 
• A meta-analysis reported a reduction in severe hypoglycemia and 
improvement in HbA1c in patients with T1DM using CSII compared with 
MDI (35). 
• A randomized controlled trial (RCT) of 32 children demonstrated that insulin 
pump therapy compared to MDI resulted in lower HbA1C levels (7.2 versus 
8.1 percent (36). 
 
Many children and their families prefer the pump to injection therapy. CSII demands 
the same amount of increased effort as MDI, but the MDI regimen may require as 
much as six to seven injections per day, which may be a barrier for some children. 
The insulin pump also appears to improve quality of life (34). 
 
In May 2011 BestPractice published a summary comparing CSII and MDI based upon 
five systematic reviews published during the time 2005-2009 (37). BestPractice 
concludes that CSII may be more effective than MDI at improving HbA1c, some 
quality of life measures and that it may reduce the frequency of severe hypoglycemia 
in those adult patients at highest risk. Because of low-quality evidence BestPractice 
do not conclude about the effects in adolescents. In the summary they have not 
reported on observational studies, but state that these studies have shown a much 
greater benefit with CSII than that observed in RCTs. Results of the observational 
studies were included by the National Institute for Health and Clinical excellence 
(NICE) in the development of recent insulin pump therapy guidance (37). 
 
Recent studies imply that the increased risk of diabetic ketoacidosis (DKA) reported 
with earlier generations of pump devices do no longer seem to be apparent (37). This 
may reflect both improvements in technology and improved diabetes education. There 
is insufficient evidence regarding the effects of long-term CSII use on complications 
and mortality. 
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!5.1.8.1.5. Whole pancreas and pancreatic islet 
transplantation 
 
Transplantation of pancreatic tissue to individuals with T1DM allows them to be 
independent of the daily insulin injections. Although it is still an experimental 
procedure, it may represent a future therapy of T1DM. The main disadvantage is the 
need for major lifelong immunosuppressive therapy.  
 
• Whole pancreas transplantation is usually performed when individuals with 
T1DM develop end-stage renal disease (ESRD) as simultaneous pancreas-
kidney transplantations. The majority of pancreas transplantations (>90%) are 
pancreas-kidney transplantations (38).  
• Pancreatic islet cell transplantation is performed by harvesting pancreatic 
islets from cadavers and injecting them into the portal vein. The islet cells 
reach and seed themselves into the liver. This remains an experimental 
therapy, but experience is accumulating (28). 
 
 
5.1.8.2.  Nutritional management and carbohydrate 
counting 
 
An important aspect of the diabetes management is giving the children with T1DM 
and their families good advice on what to eat. The children should learn good 
nutritional habits that can be implemented in their everyday life and practiced 
lifelong. It is important to include the whole family to achieve good compliance. 
Current practice regarding nutritional advice in pediatric diabetes is recommending a 
general healthy diet, as research on this topic is limited. Diabetes education should 
include teaching on how carbohydrates, fat and proteins affect blood glucose as well 
as basic dietetic advice. ISPAD guidelines recommend having a dietician in the 
multidisciplinary team (39). 
 
ISPAD recommendations of distribution of total daily energy 
Carbohydrate  50–55 %  
• Moderate sucrose intake (up to 10%) 
Fat  
 
30–35% 
• <10% saturated fat + trans fatty acids  
• <10% polyunsaturated fat 
• >10% monounsaturated fat (up to 20 %)  
• n-3 fatty acids (cis con#guration): 0.15 g /day 
Protein  10–15% 
Table 5 International Society for Pediatric and Adolescent Diabetes (ISPAD)  recommendations of 
distribution of total daily energy (39) 
 
Nutritional management can aid in glycemic control: 
• Meal planning or keeping a food plan with qualitative and quantitative advice 
on food intake can be useful. 
• Carbohydrate counting can be a good way of keeping control of the BG level 
and is used frequently as an alternative to a meal plan especially amongst 
patients on MDI or CSII.  
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!• The patients on intensive insulin regimes use an insulin-to-carbohydrate ratio 
(“carb ratio”) to calculate the dosage of insulin for each meal or snack (57).  
• Keeping a weight that is appropriate for the patient’s age and gender will be 
helpful in regulating metabolism as well as improving quality of life (40).  
 
Basic advice on diet from the CDA CPG:  
• Three meals per day at regular times and no more than six hours apart. A 
healthy snack might be beneficial. 
• Limit sugars and sweets. 
• Limit the amount of high-fat food. 
• Eat more high-fiber foods. 
• If thirsty, drink water. 
• Add physical activity to your life 
 
 
5.1.8.3.  Physical activity 
 
Physical activity is a natural part of the everyday life in most children, and with only a 
few exceptions (e.g. diving) children with T1DM should be able to do the same 
activities and sports as other children. The insulin demand decreases with increased 
level of physical activity and the insulin dosage must be adjusted to correspond with 
the amount of carbohydrates eaten and the level of exercise. Knowledge about how 
exercise influences the level of blood glucose is important to convey when educating 
children with T1DM and their families (41) as the level of physical activity may be 
reduced as a consequence of fear of hypoglycemia (42). 
 
Children and adolescents with T1DM are at increased risk of developing 
cardiovascular disease in older age compared with their non-diabetic peers. The 
atherosclerotic process starts in childhood and is accelerated in patients with T1DM. 
Youth with T1DM present early signs of atherosclerosis, as well as low physical 
activity level and cardiorespiratory fitness (43). Physical exercise improves 
lipoprotein profile, increase insulin sensitivity, lower blood pressure and improve 
cardiovascular fitness and quality of life in persons with T1DM (44). A study done in 
Switzerland showed that endothelial function is enhanced in patients with T1DM who 
practice more than 60 min/day of moderate- to-vigorous physical activity.  Motivating 
and supporting children and adolescents with T1DM to practice regular physical 
exercise is important (43). 
 
 
5.1.9. Assessment and monitoring of glycemic control 
 
Monitoring of glycemic control includes both the everyday measurements of the BG 
levels at home as well as the periodic measurement of HbA1c to assess the overall 
glycemia. The aims of monitoring is to properly adjust the insulin management to 
decrease fluctuations and avoid out of range BG levels with risk of acute and late 
complications of hypo-and hyperglycemia. Another advantage of monitoring HbA1c 
is that the data collected from each diabetes centre can be benchmarked with national 
and international standards. This might improve the local diabetes care (45). 
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5.1.9.1. Monitoring of glycemic control 
 
Self-monitoring of blood glucose (SMBG) 
Measurement of immediate glycemic control is best determined by SMBG. SMBG 
requires only a small amount of blood onto a strip that gives a read-out from a BG 
meter. The blood is often obtained using a finger stick. The frequency of SMBG is 
associated with improved HbA1c. BG monitoring is however expensive and in many 
countries the cost relative to the cost of living may make this technology unavailable. 
The ISPAD recommendations (45): 
• SMBG should be made available for all children with T1DM when financially 
possible 
• SMBG should be prescribed at a frequency to optimize each child’s diabetes 
control, usually 4–6 times a day 
• Centers caring for children with T1DM should urge nations, states, and health 
care providers to ensure that children and adolescents with T1DM have 
adequate glucose monitoring supplies. 
 
Monitoring of urine glucose 
Monitoring of urine glucose by using urine test strips is the only monitoring method 
available in many countries. Urinary glucose reflects glycemic levels over the 
preceding several hours, is affected by the renal threshold for glucose and has several 
limitations compared to SMBG (45). 
 
Continuous subcutaneous glucose monitoring (CSGM) 
While the SMBG determines the present capillary BG levels, the CSGM measure 
interstitial fluid glucose at set intervals. Minimally invasive devices are available, but 
currently expensive and may not be available in many countries. The devices have 
sensors subcutaneously that transmit readings to a receiver for readout. CSGM 
devices may particularly benefit those with hypoglycemic unawareness. As CSGM 
becomes more widely available, it is anticipated that decreased HbA1c targets may be 
achieved more safely, allowing further decreases in target HbA1c levels and 
improved outlooks for children with T1DM (45). 
 
Monitoring urinary or blood ketones 
ISPAD Guidelines state that urine or blood ketone testing should be performed during 
episodes of (45): 
• Uncontrolled hyperglycemia  
• Insulin deficiency 
• Illness with fever and/or vomiting (sick days) 
• BG values >14mmol/l in an unwell child 
• Persistent polyuria with elevated BG or urine glucose, especially if symptoms of 
DKA are present. 
 
Ketone levels can be determined by testing the urine for acetoacetate with strips or 
tablets or by testing the blood for levels of b-OH-butyrate with meters. There are 
meters available for testing of both ketone and capillary BG levels (two different 
strips). Blood ketone testing is especially important for pump patients as they have a 
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!much smaller subcutaneous insulin depot, and therefore are at risk of developing 
ketosis if insulin delivery is interrupted for any reason (45). 
 
5.1.9.2. Record keeping of glycemic control 
 
Keeping record of glycemic control is useful for the patient’s own adjustments of 
insulin treatment and for discussing at the time of consultation. The causes of 
variability in BG levels can be focused on in addition to making strategies for 
improving glycemic control. ISPAD Guidelines recommend that the record book 
should contain time and date of (45): 
• BG levels 
• Insulin dosage 
• Special events affecting glycemic control 
• Hypoglycemic episodes 
• Episodes of ketonuria/ketonemia 
 
5.1.10. Defining glycemic targets 
 
5.1.10.1. Glycated hemoglobin (HbA1c) 
 
HbA1c reflects the level of glycemia over the preceding 4–12 weeks (45). Glucose 
becomes irreversibly attached to the molecule of hemoglobin during the life cycle of 
the circulating red cell (which is approximately 120 days) forming glycated 
hemoglobin. HbA1c monitoring has been shown to be the most useful measure in 
evaluating metabolic control and is the only measure for which good data are 
available in terms of its relationship with later microvascular and macrovascular 
complications (45). 
 
5.1.10.2. HbA1c targets 
 
According to the ISPAD guidelines the target HbA1c for all age groups is 
recommended to be less than 7,5%. This recommendation is based upon the results 
from the DCCT study that intensive treatment lowers the risk of long-term 
complications. This target is intended as a guideline and each child should 
individualize its targets. Adolescents in their late teens should approach targets 
similar to adults (less than 7%) (45). 
 
While ISPAD recommend equal target HbA1c for all age groups, the CDA and the 
ADA both recommend age-adjusted glycemic targets due to the increased risk of 
hypoglycemia associated with lower HbA1c (20, 46, 47 + table 6). 
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!Table 6 Canadian Diabetes Association (CDA) recommendations of glycemic targets for children and 
adolescents with type 1 diabetes mellitus (T1DM) (20) 
 
ISPAD recommendations concerning HbA1c measurements (45): 
• Regular quality control comparisons with national and DCCT standards. 
• Facilities for measurement of HbA1c should be available to all centers caring 
for children with T1DM.  
• Every child should have a minimum of one measurement per year. (Ideally; 4-
6 measurements/year in younger children and 3-4 measurements/year in older 
children). 
 
 
5.1.11. Acute and late complications of T1DM 
 
T1DM is a lifelong condition that can lead to both short-term (acute) and long-term 
complications. T1DM is also associated with a number of comorbid conditions. The 
most common short-term or acute complications include hypoglycemia, 
hyperglycemia, DKA, and psychiatric disorders (46). The age of onset and severity of 
long-term complications varies hugely and clinical manifestations of these are rarely 
seen in childhood. The focus in this thesis will be upon the complications that occur 
in childhood.   
 
5.1.11.1. Hypoglycemia 
 
Hypoglycemia is one of the most common acute complications of T1DM, and is most 
often a result of a mismatch between insulin dose, food intake and exercise (48). 
Hypoglycemia can result in immediate signs and symptoms, permanent sequelae or 
rarely, even death. The occurrence of hypoglycemic episodes can lead to fear of 
recurrence and be a major limiting factor in attempts of reaching near normal BG and 
HbA1c levels (48, 49).  
 
Definition 
According to the ISPAD guidelines there is no consistent or agreed definition of 
hypoglycemia for the child with diabetes. BG levels below 3,3-3,9mmol/L place the 
individual at risk for severe hypoglycemia. ADA and ISPAD agree upon 
recommending the lower target for BG in children and adults with T1DM as 
3,9mmol/L (48). The CDA CPG define hypoglycemia by:  
1) The development of autonomic or neuroglycopenic symptoms; 
2) A low BG level (<4.0 mmol/L) and 
3) Symptoms responding to the administration of carbohydrate 
 
 
CDA  recommendations of glycemic targets for children and adolescents with 
T1DM  
Age (years) HbA1c (%) Considerations 
<6 <8,5 Extra caution is required to minimize hypoglycemia because of the 
potential association between severe hypoglycemia and later 
cognitive impairment 
6-12 <8,0 Targets should be adjusted to the child’s age 
13-18 $7.0 Appropriate for most adolescents 
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!Signs and symptoms  
The brain depends upon glucose for energy. Hypoglycemia results in the release of 
counter regulatory hormones such as glucagon, epinephrine, cortisol, and growth 
hormone (46). The signs and symptoms of hypoglycemia are often divided into 
neurogenic (sympathetic neural activation and epinephrine release) and 
neuroglycopenic (direct effect of hypoglycemia on the central nervous system). 
Children may also exhibit behavioral or mood changes when their BG falls, but 
remains over the normal level (48).  
 
The BG threshold for activation of autonomic signs and symptoms is related to the 
activation of the counter regulatory hormones of hypoglycemia. This threshold can be 
affected by antecedent hypo- or hyperglycemia, exercise or sleep, and thus lead to a 
decrease in symptoms of hypoglycemia during a period of time (48). This condition, 
called hypoglycemia unawareness, is defined as neuroglycopenia occurring before 
autonomic activation, as the BG threshold for neuroglycopenia neither varies as much 
with the level of glucose control nor with antecedent hypoglycemia. Hypoglycemia 
unawareness can lead to reduced awareness of the onset of hypoglycemia and thus 
result in more severe episodes. Prevention of hypoglycemia for a few weeks can 
restore hypoglycemia awareness (46, 48). 
 
Signs and symptoms of hypoglycemia  
Neurogenic (autonomic) Neuroglycopenic 
Trembling  
Palpitations  
Sweating  
Pallor 
Anxiety  
Hunger  
Nausea  
Tingling 
Difficulty concentrating  
Confusion and poor judgment 
Weakness  
Drowsiness 
Vision changes  
Difficulty speaking  
Headache  
Dizziness and unsteady gait 
Table 7 Signs and symptoms of hypoglycemia (46, 48) 
 
Severity of hypoglycemia 
Hypoglycemia has often been described as mild, moderate, or severe based on the 
individual’s ability to treat oneself. However, mild and moderate hypoglycemia is 
often considered together as there are no clinically reasons to distinguish between 
them and because younger children will almost always need to be treated by a parent 
or caregiver (48). 
 
Treatment 
The goal of treatment is to restore euglycemia. Because of the risk of rebound 
hyperglycemia and overweight, it is important to avoid overtreatment. Treatment of 
hypoglycemia should be provided promptly. Immediate intake of oral, rapidly 
absorbed, simple carbohydrate is often sufficient. Severe hypoglycemia may require 
parenteral therapy (glucagon or i.v. glucose). The amount of carbohydrate required 
will depend upon the size of the child, type of insulin therapy and proximity to recent 
insulin dosage and exercise (4). 
 
Brain dysfunction, neurologic sequelae and mortality 
Some studies have shown that hypoglycemia can lead to permanent central nervous 
system (CNS) changes and a decrease in cognitive function in children with T1DM, 
particularly in those diagnosed before the age of 5-6 years (45, 46). Recently, there 
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!has been an increased interest in the role of early-onset T1DM and chronic 
hyperglycemia (48). Some studies question the impact of hypoglycemia on long-term 
declines in cognitive function (46). A long-term follow up of the DCCT cohort found 
no evidence of substantial long-term declines in cognitive function, despite relatively 
high rates of recurrent severe hypoglycemia. In this study a large group of patients 
with T1DM was carefully followed for an average of 18 years (50). 
 
Sudden nocturnal death in young persons with T1DM has been described and is 
known as the ‘dead in bed’ syndrome. Nocturnal hypoglycemia has been implicated 
as a possible cause for these deaths (48).  
 
Risk of hypoglycemia-targets for prevention 
To avoid episodes of hypoglycemia, it is important that the child and family receives 
education about the risk factors and times when hypoglycemia is more likely to occur, 
so that they can be alert and initiate more frequent BG monitoring (20, 46, 48). 
 
Risk factors associated with hypoglycemia in patients with T1DM 
• Age of the patient (infancy and adolescence) 
• Degree of glycemic control (lower HbA1c) 
• Insulin regimen (higher insulin dose) 
• Alteration of the treatment regimen (more insulin, less food and more exercise) 
• Exercise 
• Timing, frequency, and carbohydrate content of meals 
• Acute illness 
• Psychological and socioeconomic factors including patient education and self-care behavior 
• Occurrence of a prior hypoglycemic episode 
• Increased duration of diabetes 
• Hypoglycemia unawareness 
• Autonomic neuropathy 
• Sleep 
• Alcohol consumption 
• Comorbidities (celiac and Addison’s disease) 
Table 8. Risk factors associated with hypoglycemia in patients with type 1 diabetes mellitus (T1DM) 
(20, 46, 48). 
 
A summary published by BestPractice in May 2011 and a systematic review 
published by The Cochrane Library in 2010 comparing CSII versus MDI for T1DM 
both reported that CSII may reduce the frequency of severe hypoglycemia compared 
to MDI (34, 37). 
 
5.1.11.2. Hyperglycemia and diabetic ketoacidosis (DKA) 
 
Hyperglycemia is a fairly common complication of T1DM and can be potentially fatal 
if DKA develops. Hyperglycemia occurs with postprandial relative insulin deficiency 
or at times with increased insulin needs, like during physiologic stress. If 
hyperglycemia is not adequately treated with additional insulin therapy, the body will 
begin lipid breakdown with the production and accumulation of ketoacids (2).  
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!Clinical manifestations of DKA   
• Dehydration 
• Rapid, deep, sighing (Kussmaul respiration) 
• Nausea, vomiting, and abdominal pain mimicking an acute abdomen 
• Progressive obtundation and loss of consciousness 
• Increased leukocyte count with left shift 
• Non-specific elevation of serum amylase 
• Fever only when infection is present 
Table 9. Clinical manifestations of diabetic ketoacidosis (DKA) (2). 
 
DKA results from absolute or relative deficiency of circulating insulin and the 
combined effects of increased levels of the counterregulatory hormones: 
catecholamines, glucagon, cortisol and growth hormone (28). DKA can be present at 
the initial presentation of T1DM. Patients who use an insulin pump can rapidly 
develop DKA when insulin delivery fails for any reason. However, recent studies 
imply that the increased risk of DKA reported with earlier generations of pump 
devices no longer seem apparent (37).  Monitoring BG and ketone levels regularly 
and especially during times of stress can prevent DKA. 
 
ISPAD CDA 
Biochemical criteria for the diagnosis of DKA No definitive criteria for the diagnosis of DKA 
-Hyperglycemia (blood glucose >11 mmol/L  
-Venous pH <7.3 or bicarbonate <15 mmol/L 
-Ketonemia and ketonuria 
Typically: 
-Arterial pH !7.3 
-Serum bicarbonate !15mmol/L 
-Anion gap >12 mmol/L 
- Ketonemia and ketonuria 
- BG usually "14.0 mmol/L, but can be lower 
Table 10. Criteria for the diagnosis of diabetic ketoacidosis (DKA) (20). 
 
5.1.11.3. Late complications 
 
The late complications of T1DM lead to increased morbidity and mortality in addition 
to reduced quality of life and major health costs. Most of the available experimental 
and clinical evidence suggests that the late complications of T1DM are a consequence 
of metabolic derangements, mainly hyperglycemia (53).  
 
 
The late complications of T1DM and their outcomes 
Complication Outcome 
Vascular disease Cardiac disease 
Peripheral vascular disease 
Stroke 
Nephropathy Renal failure 
Hypertension 
Neuropathy Pain 
Paresthesiae 
Muscle weakness 
Autonomic dysfunction 
Ocular complications Retinopathy 
Cataracts 
Glaucoma 
Visual impairment 
Blindness 
Table 11. The late complications of type 1 diabetes mellitys (T1DM) and their outcomes (53, 54). 
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!5.1.11.4. Growth 
 
Most children with T1DM grow normally. Poor glycemic control is associated with 
reduced weight and height, delayed skeletal and/or pubertal development (Mauriac 
syndrome) and hepatomegaly (non-alcoholic steatohepatitis). Conversely, excessive 
insulin can lead to weight gain and obesity. Monitoring of growth and physical 
development and the use of growth charts is essential in diabetes care. 
 
 
5.1.11.5. Psychiatric disorders 
 
The negative psychological impact of the diagnosis of T1DM on children and 
adolescents has been well established (46).  Depression and eating disorders are not 
uncommon. Children with T1DM have a two-fold greater prevalence of depression 
and adolescents up to three-fold greater, than their non-diabetic peers (51). In data 
from the Danish Diabetes Registry, T1DM was a risk factor for attempted suicide 
(52). Adolescent girls with T1DM are more likely to develop an eating disorder 
compared to girls without T1DM. Patients may skip insulin injections to induce 
weight loss (46). 
 
 
5.1.12. Comorbid conditions and autoimmune diseases 
associated with T1DM 
 
Children and adolescents with T1DM are at increased risk for developing comorbid 
conditions and autoimmune diseases, most commonly thyroid and celiac disease (46). 
Primary hypothyroidism due to autoimmune thyroiditis occurs in approximately 3–
8% of children and adolescents with diabetes. Celiac disease occurs in 1–10% of 
children and adolescents with T1DM (55). 
 
Comorbid conditions and autoimmune diseases associated with T1DM  
• Thyroid disease 
• Celiac disease 
• Dyslipidemia 
• Necrobiosis lipoidica diabeticorum 
• Limited joint mobility 
• Menstrual irregularities 
• Paronychia 
• Calcium, vitamin D and bone changes 
• Vitiligo 
• Primary adrenal insufficiency (Addison’s disease) 
• Lipodystrophy (Lipoatrophy and lipohypertrophy) 
• Oedema (rare) 
Table 12. Comorbid conditions associated with type 1 diabetes mellitus (T1DM)  (46,55). 
 
According to ISPAD guidelines, routine clinical examination should be undertaken 
for skin and joint changes. 
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!5.1.13. Screening for complications and comorbidity 
 
Screening for diabetes complications aims to detect subclinical complications that 
may be treated to delay progression to clinical disease (54).  The pathogenesis of 
diabetic vascular complications begins at diabetes onset, but the conditions that the 
changes may lead to remain subclinical for years. Screening for late complications is 
important because children and adolescents with T1DM rarely present with symptoms 
in the early stages of diabetes. Early detection of subclinical changes allows for 
intervention, such as improved glycemic control or secondary prophylaxis of the 
different organ systems with targeted treatment (46). 
 
Screening for and prevention of complications  
Complication Indications and intervals for screening  Screening method 
CDA ISPAD 
Nephropathy T1DM >5 years:  
Yearly screening from age 
12 years 
-T1DM >2 years: start at age 
11 years 
 
-T1DM >5 yrs: start at age 9 
years 
 
-Yearly screening 
Microalbuminuria:  
-Albumin/creatinine ratio (ACR). 
First morning urine (preferred) or 
random ACR 
-Albumin concentration (AC) 
- Albumin excretion rate (AER) in 
timed, overnight or 24-hour 
split urine collections 
Retinopathy -T1DM >5 years :  Yearly 
screening from age 15 
years 
 
-Screening interval can 
increase to 2 years if good 
HbA1c, duration of T1DM 
<10 years, and no 
retinopathy at initial 
assessment 
 
 
-T1DM >2 yrs: from age 11 
years 
 
-T1DM >5 yrs: from age 9 
years 
 
-Generally yearly screening, 
more frequently if high risk 
features. 
 
- Biannually if good HbA1c, 
duration of T1DM <10 
years, and no retinopathy at 
initial assessment 
- Direct ophthalmoscopy or indirect 
slit-lamp fundoscopy through 
dilated pupil (minimum 
assessment) 
 
-Digital fundus photography 
 
-7-standard field, stereoscopic-
colour fundus photography with 
interpretation by a trained reader 
(gold standard) 
 
Neuropathy  
 
- Postpubertal adolescents 
with poor HbA1c should 
be screened yearly after 5 
years’ duration of T1DM 
 Question and examine for 
symptoms of numbness, pain, 
cramps and paresthesia, as well as 
skin sensation, vibration sense, light 
touch and ankle reflexes. 
Dyslipidemia  -Delay screening until 
HbA1c  has stabilized 
 
-Screen at age 12 and 17 
years 
 
-Age <12 years of age: 
screen only those with 
BMI >95th percentile, 
family history of 
hyperlipidemia 
or premature CVD 
 
-Delay screening until 
HbA1c  has stabilized 
 
-Screen at age 12 and then 
every five years 
 
-screen at age 2 years if 
family history of 
hypercholesterolaemia, early 
CVD or unknown family 
history 
Fasting total cholesterol, 
 HDL cholesterol,  
triglycerides, 
 calculated LDL cholesterol 
 
Hypertension -At  least twice a year - At least annually -Use appropriate cuff size 
Table 13. International Society for Pediatric and Adolescent Diabetes (ISPAD) and Canadian Diabetes 
Association (CDA) recommendations for screening for and prevention of complications (20, 54).  
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!ISPAD recommends initial eye examination shortly after diagnosis to detect cataracts 
or major refractive errors which require treatment. ISPAD do not discuss screening 
for neuropathy, but recommend clinical assessment of neuropathy involving history 
taking and physical examination (54). 
 
Because patients with T1DM are at risk of developing other autoimmune diseases, 
both ISPAD and CDA recommend screening for thyroid, celiac and Addison disease 
(20, 55). 
 
Recommendations for screening for comorbid conditions in children with T1DM  
Condition  Indications 
for screening 
Screening 
test 
Frequency 
CDA ISPAD 
Auto-
immune 
thyroid 
disease 
All children with 
T1DM 
 
Serum TSH 
level + 
thyro-peroxidase 
antibodies 
 
At diagnosis 
and every 2 
years thereafter 
At diagnosis and every 
2 years thereafter in 
asymptomatic individuals.  
Positive thyroid antibodies, 
thyroid symptoms or goiter 
Every 6–12 
months 
More frequent than 
biannually  
Addison 
disease 
 
Unexplained recurrent 
hypoglycemia and decreasing 
insulin requirements 
8 AM serum 
cortisol 
+ serum sodium 
and potassium 
As clinically 
indicated 
 
 
Celiac 
disease 
 
All children with 
T1DM 
Tissue Trans-
glutaminase 
+ 
Immune-globulin A 
levels 
 
As clinically 
indicated 
At diagnosis 
-Annually for the first 5 
years of T1DM, then every 
second years 
Recurrent gastrointestinal 
symptoms, poor linear growth 
or weight gain, fatigue, anemia, 
unexplained frequent 
hypoglycemia, poor HbA1c or 
first-degree relative with celiac 
disease. 
More  frequent assessment 
Table 14. International Society for Pediatric and Adolescent Diabetes (ISPAD) and Canadian Diabetes 
Association (CDA) recommendations for screening for comorbid conditions in children with type 1 
diabetes mellitus (T1DM)  (20, 55). 
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!6. PART TWO  
– A comparative study between Norway and Canada 
 
6.1. Introduction and background 
 
The numbers and facts presented in this part two of our thesis are mainly based upon 
our clinical observations and interviews with the employees who we met at the 
hospitals in Norway and Canada. The Norwegian Childhood Diabetes Registry 
(NCDR) cooperates with all of the 26 pediatric wards in Norway that work with 
children and adolescents with diabetes. The NCDR publish an annual report based on 
reports and results from the different wards that describe the Norwegian national care 
of diabetes in children and adolescents. Because of the lack of a national diabetes 
register in Canada, most of the facts and numbers from Canada are based upon 
information from the employees at the hospitals and are thus less precise than the 
Norwegian data. 
 
 
6.1.1. Hospital presentation 
 
6.1.1.1. Oslo University 
Hospital, Ullevål (OUS) 
 
OUS is the largest hospital in Norway, with more than 20 000 employees. After a 
merge in September 2009 OUS now consists of what used to be four different 
hospitals in the city of Oslo; Rikshospitalet, Radiumhospitalet, Aker University 
Hospital and Ullevål University Hospital. OUS  is affiliated with the Medical Faculty 
at the University of Oslo. About 50 % of the medical research that is done at 
Norwegian hospitals originates here (56).  
 
OUS has more than 1,2 million patient contacts every year and gives medical service 
to the population in Oslo and the greater regional area of the south-eastern part of the 
country. The hospital also provides national services. The pediatric department at 
OUS, Ullevål has 415 employees and offers a wide variety of medical services. The 
pediatric medical ward has 22 beds for inpatient treatment and a pediatric 
endocrinology outpatient clinic where the children with DM are followed up. They 
care for more than 300 children and adolescents with DM every year. In 2009 there 
were in total 310 patients out of which 294 had T1DM, 6 T2DM, 8 MODY and 2 Kir 
2.6 (15).  
 
 
6.1.1.2. BC Children’s Hospital (BCCH), 
Vancouver, British Columbia, Canada 
 
 
BCCH is situated just outside the city center of Vancouver in the westernmost 
province of Canada, the British Columbia. The hospital received more than 196,000 
patient visits in 2009. In 2009, the total daily visits per month to BCCH increased by 
over 30,000 or more than 12 % since 2006, perhaps reflecting the growth in 
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!population. The hospital receives patients from a vast geographical area, and 67 % of 
patients seen every year at BCCH come from areas outside the city of Vancouver. 
(56). The BCCH is affiliated with the University of British Columbia (UBC) Faculty 
of Medicine (57).  
 
The BCCH care for more than 1000 children and adolescents with DM every year. In 
2009 there were in total 1023 patients out of which 926 had T1DM, 46 T2DM, 7 
MODY and 42 other DM subtypes (62). 
 
 
6.1.1.3.  Hospital for Sick Children (SickKids), 
Toronto, Ontario, Canada 
 
SickKids is located in the city centre of Toronto. The hospital provides the population 
of Toronto and the Ontario Province with medical care and is affiliated with the 
University of Toronto. 
 
Every year, approximately 15,000 children stay at SickKids in close to 400 beds; 
almost 300,000 visits are made to more than 100 clinics; emergency staff treats 
50,000 children and 13,000 operations are performed (58). About 1000 children with 
T1DM are followed at SickKids out of which about 940 has T1DM.  These children 
come from the Greater Toronto Area for the most part. The staff at the Diabetes 
Clinic at SickKids travels once a year to far northern Ontario (59)  
 
 
6.1.2. The Norwegian Childhood Diabetes Registry (NCDR) 
 
Norway has a national registry for pediatric and adolescent (0-18 years) diabetes, 
NCDR, established in 2006 with a conjunction of the Norwegian Diabetes Registry 
and the “Pediatric Diabetes and Quality”.  The NCDR is based on the “Norwegian 
Studygroup for Childhood Diabetes”, a network of pediatricians and nurses 
specializing in and working with DM.  
  
The NCDR is based on a signed consent from the child and the parents. All types of 
DM are included in the registry and data is collected from every reported new case 
(incidence rates). When a child is newly diagnosed with DM a standardized form of 
notification is filled out and sent to NCDR. The form contains information on age, 
sex, ethnical background, familial heredity, other diseases, height, weight and 
pubertal stadium, lab-works, treatment given at the ward and what treatment the child 
will have at discharge.  
 
Every year all 26 pediatric wards in Norway that treats children and adolescents with 
diabetes send rapports with the results from an annual examination of their patients to 
the NCDR. From 2008 all pediatric departments in Norway have participated. The 
rapports are standardized forms with documentation of questionnaires and clinical 
examination. A rapport is returned to each ward with their local data and a national 
rapport with benchmarking results. The numbers of patients participating in the yearly 
examinations has been rising since the beginning of registration in 2001. The 
percentage of participating patients in the annual examination  in 2009 was 92% 
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!(range 54-100%). The registry has data from 1973 on incidence rates and is a database 
for research (14). 
 
 
Fig. 5. Number of patients participating in the annual diabetes controls in Norway 2001-2009 (14) 
 
 
6.2. Results 
 
6.2.1. Diabetes education and follow-up at diagnosis 
 
OUS 
When a child is diagnosed with T1DM at OUS, he or she is admitted for an average 
inbed length of stay of 11 days, together with his/hers parents. Depending on the 
child’s condition, age and family the period may vary from 6 to 14 days. Initial 
treatment is started and the child and the family receive education from the diabetes 
team during this first stay at the hospital. They have separate appointments with each 
of the professional members of the diabetes team (doctor, diabetes nurse, dietitian, 
social worker, psychologist). The doctor treating the child in this initial stay will 
continue as this patient’s doctor in the years to come. The diabetes team consider this 
initial stay at the hospital very valuable as the child, its family and the diabetes team 
get to know each other very well. During this initial stay the patient sleeps at home for 
some of the nights. This is a part of the education allowing the family to learn how to 
deal with their new situation while the diabetes team can control that the family 
establishes good routines. The doctor will often give his or her personal phone 
number to the family to make the family feel confident and secure.  The staff at OUS 
finds that there are several advantages of hospital admittance after diagnosis, 
especially that the patient and family feel safe and taken good care of. The members 
of the diabetes team are able to build a trustworthy and close relationship with the 
child and the parents and can follow them closely to make sure that they comprehend 
the education and manage the diabetes care properly. The diabetes nurses do visits to 
schools and kindergardens (15).   
 
BCCH 
BCCH provides families with a newly diagnosed child with T1DM a Diabetes Day 
Program (DDP) which is a full three days program where the child’s primary 
caregivers together with the child receive education on how to manage T1DM.  The 
family is not hospitalized but stays in a close by hotel. The child is served all meals at 
the hospital and the parents are instructed in insulin injection techniques, type and 
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!dosage of insulin etc. A diabetes nurse educator together with a dietitian is 
responsible for this training. They do all insulin injection, check the BG levels and do 
the urine checks. Between the meals the family is educated on different topics 
concerning the management of T1DM. Physicians, a social worker and psychologist 
are also part of the diabetes team (57).  
 
SickKids 
Children who are newly diagnosed with T1DM come as outpatients with their 
families to the diabetes day care unit at the hospital for two days from breakfast till 
supper. The child is assigned a core team consisting of one nurse, a physician and a 
social worker. The first two days the family receives initial education that consists 
mostly of one-to-one teaching, but sometimes also group teaching. After the first two 
initial days, the family has four following sessions spaced with one week. Each 
session is three hours; one hour with the doctor and two hours with the nurse. 
Sometimes they see the social worker or psychologist, according to the individual 
child’s or family’s needs. Their first clinic visit is approximately 6-8 weeks after the 
diagnosis. After this they receive follow-ups every three months (59). 
 
After the day care and when the family has proven that they manage the insulin 
therapy, they are discharged from the hospital and receive a contact telephone number 
to their designated nurse. The family is advised to test the blood glucose four times a 
day and report the 24h BG. The family will usually call their nurse every day for the 
first two weeks and then less frequently for insulin dosage advice and for general 
advice (e.g. concerning special activities like sports or birthday parties). The family 
will usually provide the school/kindergarten with the information they need, but the 
staff from the core team can do school visits if there are any difficulties (59). 
 
6.2.2. Diabetes multidisciplinary team  
 
There are many similarities on the composition of diabetes teams in Norway and 
Canada (table 15).  The Norwegian Diabetes Association has made a national 
standard for diabetes teams in Norway describing the team’s tasks and composition 
(60) and the Norwegian Ministry of Health and Care Services made a national 
strategy for diabetes in the years 2006-2010 emphasizing the importance of the 
diabetes team in the management of DM (61). The most common health workers of 
the team in both Canada and Norway are: physicians with a specialty in pediatrics and 
special knowledge on diabetes, nurses with special knowledge on diabetes, dietitians, 
a social worker and a psychologist. This is in accordance with the ISPAD and CDA 
guidelines. Table 15 shows a comparison of the composition of the diabetes 
multidisciplinary teams between the hospitals in Norway and Canada. 
 
6.2.3. Follow-up 
 
OUS 
Patients at OUS are seen by their physician and most often a diabetes nurse at the 
pediatric outpatient clinic every three month or more frequently if needed. The 
diabetes team is available by telephone 24 h for advice. Social workers, dietitians or 
psychologists are not seen on a regular basis, but called on when needed. The patient 
keeps a diabetes diary that he or she brings to the consultation. This makes a basis for 
discussion and targeted follow up. Special problems or concerns are discussed. The 
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!focus is both on what is good and what is not so good. At every consultation the 
HbA1c is measured and the physician looks for lipohypertrophy (fatty lumps) in the 
skin. Once a year growth charts and developmental stages are recorded (15). 
 
BCCH 
In BCCH, they would ideally see the children less than 5 years of age every three 
months and the older children every six months. In reality they saw the youngest 
children every four months and the older ones every eight months. Patients living far 
away would usually attend BCCH once a year and ideally see their local pediatrician 
in between visits to measure their HbA1c every three months. The patients all have 24 
h access to a member of the diabetes team in case of emergencies. The nurses are 
available over phone, fax or e-mail and receive about 200 phone calls every week. 
Once a year the diabetes team would travel to one or two cities in distant areas of the 
province, e.g. Edmonton or Calgary. The no-show rate at BCCH was 5-10% (62).  
 
SickKids 
At Sick-Kids they usually see their patients every three months. The children mostly 
come from the Greater Toronto Area, with a mean travel time of 30-60 minutes. A 
few families living outside of Toronto chose to do their follow-ups at SickKids.. 
About once a year the diabetes team travels to distant areas of the province, e.g. far 
northern Ontario (59). 
 
 OUS BCCH SickKids 
Who makes 
the diagnosis? 
General practitioner or hospital 
doctor 
Usually the General 
practitioner 
Hospital doctor 
Admission at 
diagnosis? 
Admission 11 days on average Only if presenting with 
diabetes ketoacidosis 
Only if presenting with 
diabetes ketoacidosis 
Composition 
of the diabetes 
multi-
disciplinary 
team 
-Physicians with special interest in 
pediatric diabetes (every child have a 
primary assigned physician) 
-3 diabetes nurses (210 % position) 
-2 social workers (2x20 % position) 
-1 dietitian (40 % position) 
-1 psychologist (50 % position) 
-5-6 nurses 
-6 physicians 
-2 dietitians 
-1 social worker 
-psychologist available  
-7 physicians (usually 
pediatric endocrinologist) 
-5 diabetes nurses  
-3 diabetes dietitians 
-1 social worker or 
counselor 
-Psychologist (part time) 
Education -At the time of diagnosis. 
- Most often individual, separate 
appointments with each of the 
members of the diabetes team. 
 -Group sessions with parents twice a 
year for all newly diagnosed last six 
months.  
-Once a year group sessions with 
every 12 year old patients without 
their parents.  
-At the time of diagnosis. 
(Diabetes Day Program -
outpatient). 
-Re-education is given 
individually and in 
groups. Once a month 
group teaching for 
patients living far away, 
they can stay overnight. 
-At the time of diagnosis. 
Diabetes Day Care 
(outpatient). 
-Access Clinic for 
teenagers with HbA1c% 
>10 for more than two 
visits in a row, open two 
days a week, diabetes 
team available. 
Follow-up -After diagnosis and discharge from 
the hospital they come in for an 
appointment after one week, next one 
after two weeks, then after four 
weeks, two months and then every 3 
month. 
-Daily telephone contact first period 
after diagnosis. 
<5 years: every 3 month 
(but in reality every 4 
month) 
>5 years: every 6 month 
(but in reality every 8 
month) 
-Every 3 month 
Table 15. A comparison between Oslo University Hospital (OUS), BC Children’s Hospital (BCCH), 
Vancouver and Hospital for Sick Children (SickKids), Toronto  in regards to admission at diagnosis, 
composition of the diabetes multidisciplinary team, education and follow-up.  
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!6.2.4. Treatment – choice of insulin regimens 
OUS 
Data from the NCDR annual report in 2009 show that almost all the children with 
T1DM in Norway are on an intensive insulin regimen (table 16). Approximately two 
thirds of the youngest children (under 5 years) are on pumps.  
 
 Age (years) 
 <5 5-9 10-14 >15 Total 
Diet only 0 0 0 0 0 
Antidiabetes tablets 0 0 0,1 0,5 0,2 
Insulin pen 35,3 47,5 44,3 51,8 47,2 
Premixed 0 0,5 0,6 0,7 0,8 
Insulin pump 64,7 52,0 55,1 47,5 52,0 
Table 16. Number of patients (%) with type 1 diabetes mellitus that are on the different types of 
diabetes treatments (14). 
The percentage of children that use insulin pumps in Norway varies between the 
pediatric wards, with a range from 13-81%. (fig. 7). Every child that is diagnosed 
with T1DM at OUS is offered an insulin pump regardless of the child’s age. In 2009, 
62% of the children with T1DM at OUS were on pumps. Close to all of the remaining 
38% children are on MDI. Almost no child use less than three daily injections. Most 
of the patients on MDI use pens as opposed to syringes (14). 
 
 
Fig.6. The portion of patients (%) on insulin pump therapy in the different pediatric wards (a-æ) in 
Norway at the annual examination in 2009 (14) 
 
The data from Canada is based on numbers from a database on BCCH and from 
interviews with the staff at SickKids (table 16). 
 
 
 
 
 
 
 
Table 16 Choice of insulin regimen at the Oslo University Hospital (OUS), BC Children’s Hospital 
(BCCH), Vancouver and Hospital for Sick Children (SickKids), Toronto. 
 
 
Insulin regimen OUS BCCH SickKids 
Insulin pump 62% 32 % 30(-40)% 
MDI 38% 4 % 10% 
Conventional regimens (injections) 0 64 % 50-60% 
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!BCCH 
At BCCH all the patients are started on a conventional regimen with a combination 
therapy of NPH and short-acting insulin. They are encouraged to use pens, but get the 
choice of using syringes. The staff at BCCH prefers to have known the family for a 
year and that the child has had T1DM for a year before they offer changing to CSII, 
unless the family ask for and wants a pump (62). 
 
SickKids 
All the children at SickKids are started on insulin injection therapy, regardless of the 
age of the child, except perhaps if the child has a sibling who uses an insulin pump. 
The government finances the pumps and some of the pump supplies when the child 
has had T1DM for a year and when certain criteria are met (e.g. three clinic visits in a 
year, HbA1c less than 10%). The family and child are assessed at the time of 
diagnosis to consider if MDI are an appropriate treatment. If not, the insulin treatment 
is simplified and the patients are put on a two-injections-daily regiment (59). 
 
 
6.2.5. Glycemic control and glycemic targets 
 
 
OUS 
The study group in NCDR follows the ISPAD recommendation of HbA1c < 7,5% in 
children 0-18 years. In 2009 the annual report from NCDR shows that the mean 
HbA1c was 8,7% in Norway and 8,6% in OUS. The mean HbA1c in the different 
departments are benchmarked (14). 
 
 
Fig.7. HbA1c from the different Norwegian pediatric wards caring for children with diabetes (a-æ) 
measured at Aker University Hospital in 2009 (14). 
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 Fig.8. HbA1c measured at Oslo University Hospital, OUS, Aker in 2009, distributed on age and sex of 
the patients (14) 
 
BCCH and SickKids 
Both BCCH and SickKids follow the CDA CPG in regards to glycemic targets.  CDA 
recommend age-adjusted glycemic targets due to the increased risk of hypoglycemia 
with lower HbA1c. The mean HbA1c was reported by the staff at BCCH and Sick 
Kids to be 8,3% in 2009. It is not known if these hospitals do benchmarking on 
HbA1c.  
 
 
6.2.6. Complications 
 
The most serious acute complications that can arise in children with T1DM are severe 
hypoglycemia with unconsciousness and/or seizures and diabetes ketoacidosis (DKA) 
from hyperglycemia. Both complications are due to failure of proper insulin dosage to 
the BG level, with either too little insulin (leading to hyperglycemia) or too much 
insulin (leading to hypoglycemia). The NCDR register number of patients 
hospitalized with DKA, severe hypoglycemia and hypoglycemia that requires help 
from another person (14). 
 
Number of patients 
presenting with DKA 
at diagnosis %  
Number of patients 
hospitalized with 
DKA % (numbers) 
Number of patients 
hospitalized with 
hypoglycemia % 
(numbers) 
Number of patients 
with hypoglycemia 
that requires help % 
(numbers) 
NCDR Sick
Kids 
BCC
H 
NCD
R 
Sick
Kids 
BC
CH 
NCDR Sick
Kids 
BCCH NCDR 
25 18 20 5 
(113) 
5-12 - 7 (155) 10-15 - 8 (166) 
Table 17.  The occurence of diabetes ketoacidosis (DKA) and hypoglycemia in 2009 in Norway (The 
Norwegian Childhood Diabetes Registry (NCDR)) and in Canada (British Columbia Children’s 
Hospital (BCCH) and Hospital for Sick Children (SickKids)) (14, 59, 62). 
 
The number of patients on insulin pumps has increased from 15% to 52% in Norway 
over the years 2002-2009. There has not been an increase in DKA during this time 
(14). 
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!6.2.7. Screening for autoimmune diseases and late 
complications 
 
Because of the correlation of the duration and level of hyperglycemia and degree of 
complications, optimal diabetic control is important from the time of diagnosis and 
throughout life. Childhood and adolescence is a period during which intensive 
education and treatment may prevent or delay the onset and progression of 
complications (54). The DCCT showed a 60% reduction in developing complications 
over 9 years when the HbA1c was kept at around 7 % in T1DM (31).  
 
Norway adheres to the ISPAD recommendations for screening of late complications 
and comorbidity. At SickKids they do not screen for comorbidity until puberty or 
when the patients have had the diagnosis for more than 5 years and are more than 12 
years of age. They then screen every two years or more frequent if the patients have 
positive findings (18). At BCCH they screen more often. According to Dr. Metzger 
they take both the CDA and ISPAD Guidelines into consideration as the ISPAD 
Guidelines are published more recently (2009 compared to CDA from 2008). Both 
thyroid and celiac disease are screened for biannually or if clinically suspected. 
Screening for retinopathy and nephropathy starts at age 10 or after five years of 
T1DM (62). 
 
 
 NCDR  
(Yearly screening) 
Number of patients (%) 
screened in 2009 
SickKids  BCCH 
Nephropathy 86% T1DM >5 years:  
Yearly screening from age 12 
Yearly at age 10 or after 5 
years of T1DM 
Retinopathy 35% When clinically indicated Yearly at age 10 or after 5 
years of T1DM 
Thyroid disease 98% Yearly for hypothyroidism At diagnosis and then 
biannually 
Celiac disease 98% Once in year of diagnosis, 
then biannually or if suspected 
At diagnosis and then 
biannually 
Table 18 Screening for late complications and co morbid conditions in type 1 diabetes in children 0-18 
years in Norway (The Norwegian Childhood Diabetes Registry (NCDR) and Canada (British Columbia 
Children’s Hospital (BCCH) and Hospital for Sick Children (SickKids)) (14, 18, 62). 
 
 
6.3. Discussion 
 
6.3.1. Hypoglycemia-parental fear 
 
Fear of hypoglycemia can result in poor glycemic control. While attending diabetes 
clinics in Canada, we met multiple families that struggled with the dilemma of 
whether to keep the BG levels higher than the recommended targets in order to 
prevent hypoglycemic episodes or try to keep the BG levels at recommended lower 
levels and thus increasing the risk of experiencing hypoglycemic events.  Quite a few 
of the families of the youngest patients attending clinics admitted to giving their child 
a snack when SMBG would show BG levels at 4,5 or even higher.  Some of these 
children were slightly overweight. Based upon our observations attending diabetes 
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!clinics, we wondered whether there could be an association between parental fear of 
hypoglycemia and children with poor glycemic control.  
 
Dr. Denis Daneman at SickKids defines three issues to suggest why hypoglycemia 
can be an obstacle to keeping glycemic control (10): 
1. Fear of hypoglycemia. 
• Often interferes with an individual’s ability to achieve near-normal 
glycemic concentrations  
• Might be based on previous experiences with hypoglycemia or it may be 
part of wider anxiety about diabetes.  
2. Hypoglycemia unawareness 
3. Episodes of severe hypoglycemia  
• Predisposes to further episodes, as a result of downgraded regulatory 
responses to repeated hypoglycemic events. 
• Reassessment of glycemic targets and perhaps the insulin regimen is 
needed. 
 
A systematic review looking at fear of hypoglycemia in parents of young children 
with T1DM was published in 2010 (63). The aim was to systematically review studies 
concerning the extent and consequences of fear of hypoglycemia in parents of 
children less than 12 years of age with T1DM and interventions to reduce such fear. 
Knowing that patients and families are afraid of hypoglycemia, they hypothesized and 
aimed to evaluate the effectiveness of any interventions designed to prevent that (49): 
1. Fear of hypoglycemia might take precedence over concern about long-term 
complications. 
2. Behavior to avoid hypoglycemia might be at the cost of poorer control. 
 
Results and conclusion from this review: 
• Parental fear of hypoglycemia, anxiety and depression are common, affecting 
both parental health and quality of life.  
• Hypoglycemia avoidance behaviors by parents might adversely affect glycemic 
control.  
• No interventions that reduced parental fear of hypoglycemia were found. 
• Trials of interventions to reduce parental anxiety and hypoglycemia avoidance 
behavior are needed.  
 
It is important to uncover and address parental fear of hypoglycemia at an early stage, 
so that the parents feel secure and safe in managing the diabetes care of their child. 
The diabetes team at OUS finds that the diabetes education and the relationship being 
built between the diabetes team and family at the hospital during the first week after 
diagnosis is extremely valuable in order to make the family and child feel confidence 
and to reveal and address areas of uncertainty in regards to diabetes management (15).  
 
 
6.3.2. Diabetes education and follow up 
 
Follow-up at diagnosis 
While OUS admit all children with newly diagnosed T1DM regardless of the 
presence of DKA, BCCH and SickKids do not admit children with newly diagnosed 
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hospitals we visited offer an outpatient educational program that the children attend 
together with their parents. The programs are similar with regards to what they teach 
the patients in Norway and Canada. At OUS the patient is admitted to the hospital 
with an average length of stay of 11 days. While this could initially seem as 
economically expensive, the knowledge about the particular child and family and the 
safety that the family feels is considered to be very valuable in the future diabetes 
management and follow-ups.   
 
Diabetes education 
At all of the three hospitals we visited the patients and their parents were given an 
initial education at the time of diagnosis. In BCCH many of the patients receive most 
of the education from local pediatricians, but they are offered to come in for teaching 
sessions with an overnight stay at BCCH. At OUS and SickKids most of the 
education is given at the hospital. All three hospitals give families a telephone number 
for close contact the first period after diagnosis. OUS was the only hospital where 
doctors gave away their personal phone number to the patients. We did not get the 
impression that patients or parents abused this way of contact. 
 
Diabetes multidisciplinary team 
There are many similarities on the composition of diabetes teams in Norway and 
Canada.  The most common health workers of the teams are physicians with a 
specialty in pediatrics and special knowledge on diabetes, nurses with special 
knowledge on diabetes, dietitians, a social worker and a psychologist. This is in 
accordance with the ISPAD and CDA guidelines. 
 
Follow-up 
While attending clinics in Canada we found that one of the differences between the 
hospitals was who the children saw at check-ups and how much time spent with each 
member of the team.  While many of the patients at BCCH would travel around ten 
hours to come to check-ups, the families at SickKids would rarely travel more than 
four hours. Mean travel time for the patients at OUS is very short, seldom more than 
two hours. Because the children and families followed at BCCH often would have 
had to travel far to get to the clinics, they would try and spend at least an hour and a 
half with the patients. At SickKids we found that they would be more time efficient. 
One of the doctors at SickKids said that at a normal day at the diabetes clinic he 
would see 30-50 patients, aiming at keeping the number under 40.  
 
At OUS a regular check-up includes about 30 min with the physician and five to ten 
min with the diabetes nurse. 
At OUS and SickKids the children are seen every three month. In BCCH we were 
told that they see their patients more seldom, the youngest children under five years 
they try to see every three month but in reality they see them every four month. The 
children over five years they try to see every sixth month, but in reality they see them 
every eight month. According to ISPAD guidelines a child with T1DM should be 
seen at least three to four times a year. BCCH does not meet this recommendation 
with every patient. We got the impression that this is at least partly because of the 
long travel distances in British Columbia. 
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In controlled studies (e.g. the DCCT) intensive regimen has been demonstrated to 
achieve better glycemic control and reduce the incidence of long-term sequelae 
compared to conventional insulin therapy. It is recommended to be selected whenever 
possible (20, 24, 30, 31). 
 
More emphasis has been on intensive insulin regimens ever since the DCCT showed 
reduced complication rates with tighter glycemic control. A systematic review 
published in The Cochrane Library in 2010 comparing CSII versus MDI for T1DM 
found that there was a statistically significant difference in HbA1c favoring CSII over 
MDI  (34). 
 
At OUS almost two thirds of the children with T1DM were on pumps, compared to 
both the Canadian hospitals were only one third of the children were on pumps. More 
surprisingly, about two thirds of the children are on conventional regimens, compared 
to almost none at OUS. This is, however, according to CDA guidelines (20). While 
ISPAD guidelines recommend consideration of an intensive insulin regimen (30), 
CDA guidelines recommend that children with new-onset diabetes should be started 
on at least 2 daily injections of short- or rapid- acting insulin analogues combined 
with an intermediate- or long-acting insulin. CDA recommend that the insulin therapy 
should be assessed at each clinical encounter to ensure that it still enables the child to 
meet HbA1c targets, minimizes the risk of hypoglycemia and allows flexibility in 
carbohydrate intake, daily schedule and activities. This assessment should include 
consideration of a change to CSII therapy. According to CDA CSII is safe and 
effective and can be initiated at any age (20). While every child that is diagnosed with 
T1DM at OUS is offered to start with an insulin pump at diagnosis, both the Canadian 
hospitals we visited preferred to wait for a year before putting the child on such 
therapy. The staff claimed that they preferred to have known the child and family for 
a year to consider if they are qualified for managing CSII therapy. In Ontario the 
government finances the pumps only when the child has had T1DM for a year (59). 
This might influence the choice of postponing pump therapy. 
 
At BCCH we learned that there are no school nurses in Canada, but that they have a 
nursing support services system (the “NSS” ) that look after children, generally from 
preschool until end of 3rd grade. These are not nurses, but they keep an eye on the 
children with T1DM; make sure that they eat their snack and measure the BG levels, 
but they don’t give insulin in school. According to Dr. Metzger at BCCH there is 
nowhere in Canada where the school personal can press the button on the insulin 
pumps or give injections of insulin in schools. Either the children have to do it with 
guidance from a caretaker over the phone, or someone has to come to school to do it 
for them. This is, according to Dr. Metzger, one of the reasons why they don’t have 
many kids on MDI (62). According to Janet, one of the diabetes nurses at SickKids, 
this also applies for their patients. Because no one in school can press the button on 
the insulin pump for the children at lunchtime or supervise the children while they 
push the button themselves, only a few of the youngest children are on pumps. This is 
a rare problem in Norway where the children often will have the staff in the school or 
kindergarten assisting them with their insulin administration. We found it unfortunate 
that such circumstances could influence whether or not children with T1DM is 
recommended and receives the best therapy available. While every child at OUS is 
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the pump and ask for it to get it at SickKids (59).  
 
 
6.3.4. Glycemic control and glycemic targets 
 
Glycemic control 
The DCCT and similar studies provides clear evidence that better glycemic control in 
adults and adolescents, as measured by a lower HbA1c level, is associated with fewer 
and delayed microvascular complications. The DCCT showed a 60% reduction in 
developing microvascular complications over nine years when the HbA1c was kept at 
around 7 % in T1DM (31).  ISPAD state that there is no reason to believe that this is 
not also the case in younger children (30). 
 
Glycemic targets 
While ISPAD recommend equal target HbA1c for all age groups, the CDA and the 
ADA both recommend age-adjusted glycemic targets due to the increased risk of 
hypoglycemia associated with lower HbA1c (20, 46, 47).  
 
 
Figure 9. In the diabetes control and complications trial group ( DCCT), there was a progressive 
increase in the incidence of severe hypoglycemic episodes (per 100 patient-years) at lower attained 
HbA1c values during intensive insulin therapy in patients with type 1 diabetes mellitus. Data from The 
DCCT Research Group (31) 
 
 
 
 
 
 
 
 
 
Table 19 Recommendations of HbA1c in children and adolescents with type 1 diabetes mellitus 
(T1DM) according to International Society of Pediatric and Adolescent Diabetes (ISPAD), American 
Diabetes Association (ADA) and Canadian Diabetes Association (CDA). (20, 47) 
Comparison of ISPAD, ADA, and CDA recommendations of 
HbA1c goals in children and adolescents with T1DM  
Age (years) HbA1c (%) 
ADA and CDA ISPAD 
<6 <8,5 <7,5% 
6-12 <8,0 
13-18 $7.0 
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According to ISPAD there is evidence in many studies that the risk of hypoglycemia 
increases as the HbA1c decreases, but this is not always the case. The ISPAD 
guidelines state that glycemic control and the risk of hypoglycemia may be decreased 
by the choice of insulin regimens and the frequency of BG monitoring (e.g. severe 
hypoglycemia appeared to be reduced in those using CSII compared to MDI regimen  
(34)). Careful attention to avoid severe hypoglycemia is important, and it is 
recommended by ISPAD that when hypoglycemia unawareness is present, glycemic 
targets should be increased until hypoglycemia awareness is restored. The youngest 
children (under 6 years) are at increased risk for adverse neurologic outcomes from 
severe hypoglycemia as they are unable to self-identify hypoglycemia, ISPAD state 
that caution in achieving lower targets for younger children is appropriate (45). 
 
Short-term risks of hypoglycemia include potentially dangerous circumstances that 
may arise when someone is hypoglycemic, e.g. while climbing a tree. Long-term 
consequences of severe, long lasting or repetitive hypoglycemia might include mild 
cognitive impairments in teenagers with early onset T1DM or older adults with 
longstanding disease. (45). Controversy remains about whether cognitive effects in 
young children are a result of severe hypoglycemia or rather due to effect of chronic 
hyperglycemia (10).  
In 2009 the mean HbA1c at OUS, SickKids and BCCH did not differ much (8,6% at 
OUS compared to 8,3% at both the Canadian Hospitals). However, the target for 
glycemic control varies between the different countries. While Norway adhere to the 
ISPAD guidelines of a target HbA1c < 7,5%, the Canadian Hospitals follow the CDA 
age-adjusted targets with higher target HbA1c for children less than 12 years of age. 
The goal of diabetes management should be to achieve a HbA1c value as close to 
normal as possible to avoid the long-term micro- and macrovascular complications of 
DM, while at the same time avoiding complications associated with both hypo- and 
hyperglycemia 
 
 
6.4. Summary 
 
During the last century T1DM in the western part of the world has evolved from 
being a fatal disease with certain death short time after diagnosis to becoming a 
disease that is rapidly increasing in incidence and associated with increased long-term 
morbidity and mortality. The US Centers for Disease Control recently estimated that a 
10-year-old boy or girl developing diabetes in the year 2000 would lose, on average, 
18,7 and 19,0 life-years, respectively, compared with non-diabetic peers (10).  
Optimal diabetes management is important to avoid or delay the long-term 
complications of DM.  In addition to optimal diabetes treatment, tight glycemic 
control and avoidance of the short-term complications of diabetes while screening for 
long-term complications and co morbidities associated with diabetes, diabetes 
education remains a cornerstone in this work. The hospitals we visited in Norway and 
Canada all had well-organized diabetes care and did for the most part practice 
according to international guidelines of pediatric diabetes. 
 
Diabetes treatment has evolved gradually after the discovery of insulin in 1922, but a 
cure for diabetes remains to be found.  Intensive insulin regimens have been shown to 
achieve better glycemic control and reduce the incidence of long-term sequelae in 
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!adults and adolescents compared to conventional insulin therapy (10, 24, 30, 31). It 
has also been demonstrated that CSII is favorable to MDI in terms of reaching lower 
HbA1c targets and possibly increased quality of life measures and reduced frequency 
of severe hypoglycemic events (34, 37). While every child diagnosed with T1DM at 
OUS is offered to start with an insulin pump at diagnosis, all the children at SickKids 
are started on insulin injection therapy and both the Canadian hospitals we visited 
preferred to wait for a year before beginning with CSII. Compared to OUS, where 
almost two thirds of the children with T1DM are on pumps, both the Canadian 
hospitals have only got one third of the children on pumps. More surprisingly, in 
Canada about two thirds of the children are on conventional regimens, compared to 
almost none at OUS.  According to Dr. Metzger at BCCH one of the reasons why 
they don’t have many children on MDI is because there is no one at school that can do 
the injections for them (18, 62). 
 
The DCCT and similar studies, provides clear evidence that better glycemic control in 
adults and adolescents, as measured by a lower HbA1c level, is associated with fewer 
and delayed microvascular complications (31). While ISPAD recommend equal target 
HbA1c < 7,5% for all age groups, CDA recommend age-adjusted glycemic targets 
due to the increased risk of hypoglycemia with lower HbA1c. According to ISPAD 
there is evidence in many studies that the risk of hypoglycemia increases as the 
HbA1c decreases, but that this is not always the case. 
 
Controversy remains about whether cognitive effects in young children are a result of 
severe hypoglycemia or rather due to the effect of chronic hyperglycemia (10). A 
systematic review looking at fear of hypoglycemia in parents of young children with 
T1DM showed that there is some suggestion that hypoglycemia avoidance behaviors 
by parents might adversely affect glycemic control (63). A thorough diabetes 
education, frequent follow-up 
s and a well-established relationship between the physician and the children with 
T1DM and their families can be helpful in uncovering and addressing parental fear of 
hypoglycemia at an early stage to ensure confidence and safe diabetes care. 
 
 
6.5. Conclusion 
 
Optimal diabetes management to avoid the short- and long-term complications is 
important as T1DM is a chronic condition associated with increased morbidity and 
mortality. Children with T1DM should, where possible, receive the best diabetes care 
available. Tight glycemic control and intensive insulin regimen has been shown to 
reduce and delay the diabetes late complications and should be included as part of the 
management of childhood diabetes. 
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!8. Appendix 
QUESTIONNAIRE – DIABETES (T1DM and T2DM) IN 
CHILDREN: A GLOBAL PERSPECTIVE 
 
This questionnaire is designed to gather information about children less than  15 years 
of age with diabete. The interview consists of two parts. Each part should not last 
more than 1 hour. 
 
The first part is designed to map diabetes in children at a national or regional level, 
and the interviewer fills out this first part of the interview based on information 
available on the internet and other available sources. The information will then be 
quality assessed with the local informant. 
 
The second part is designed to map how children with diabetes are followed up at the 
local hospital/treatment centre. The interview contains multiple open, qualitative 
questions. The interview will therefore be tape-recorded and the tape recordings will 
be transcribed before the analysis takes place. 
 
The questionnaire does not ask for personal sensitive information. 
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!Country: 
Region/county/state: 
Date: 
Informant: name/occupation  
Interview by: 
PART 1 
Incidence  
 
 
1. The annual incidence of the different types of diabetes in this country (enter the 
number and percentage) 
• Type 1 diabetes (T1D) 
• Type 2 diabetes (T2D) 
• Gestational diabetes 
 
2. The incidence of T1D and T2D among children under 15 years of age 
o The total incidence: 
o How is the distribution in the following groups of ages (estimated): 
o <5 years 
o 5-<10 years 
o 10-<15 years 
o > 15 years 
 
3. What is the gender distribution among children with T1D and T2D in the country? 
 
 
4. What are the overall proportions of the following ethnicities in this country: 
o White / European background (non-Hispanic whites)  
o Black / African background  
o Middle-East / North-African  
o Indian subcontinent  
o East-Asia 
o Middle- and South American (Hispanics)  
o Indigenous (specify) 
o Mixed (or unclassified) 
 
5. How many children with diabetes in this country are 
o White / European background (non-Hispanic whites)  
o Black / African background  
o Middle-East / North-African  
o Indian subcontinent  
o East-Asia 
o Middle- and South American (Hispanics)  
o Indigenous (specify) 
o Mixed (or unclassified) 
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!Prevalence  
 
6. What is the prevalence of T1D and T2D among children in the following groups 
of age? 
o <5 years 
o 5-<10 years 
o 10-<15 years 
o " 15 (adults) 
 
Mortality 
 
7. What is the average life expectancy in the country? 
o Women: 
o Men: 
 
 
8. What is the average life expectancy among patients diagnosed with T1D before   
the age of 15?  
o Women: 
o Men: 
 
 
National health  
 
9. How many doctors per citizen? (This will differ depending on location; city, rural, 
town etc) 
 
10. Is there a geographical difference in availability of doctors? 
 
11.  What is the gross domestic product (GDP) of the county? 
 
12. What is the total expenditure on health as a percentage of the GDP? 
o Which proportion is financed by the public? 
o Which proportion is financed by private actors? 
 
13. Which proportion of the national budget is spent on health? 
 
14. Does the public health care system finance the costs associated with diabetes 
medication and equipment? 
o Yes 
o No 
 
15. If the answer is yes on question 14, which medication is financed?  
o Insulin 
o Yes 
! _________% financed 
o No 
o Antidiabetic drugs 
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!o Yes 
! _________% financed 
o No 
 
          Glucagon 
o Yes 
               ____________% financed 
o No 
 
 
16. If yes on question 14, which of the following materials is financed  
o Syringes: 
o Needles: 
o Insulin pen: 
o Insulin pump: 
o Materials for the unconsciousness insulin pump: (needle, catheter, reservoir 
etc): 
o Home Blood Glucose meters: 
o Blood glucose test strips:  
o Finger-pricking devices: 
o Lancets for finger-pricking: 
o Continuous subcutaneous glucose monitoring devices: 
o Urine sticks to check for ketonuria: 
o Other:_____ 
 
17. If the answer is yes on question 14, does the patient have to pay anything? If so, 
how much? (%) 
o Syringes: 
o Needles: 
o Insulin pen: 
o Insulin pump: 
o Materials for the insulin pump: (needle, catheter, reservoir...): 
o Home Blood Glucose meters: 
o Blood glucose test strips:  
o Finger-pricking devices: 
o Lancets for finger-pricking: 
o Continuous subcutaneous glucose monitoring devices: 
o Urine sticks to check for ketonuria: 
o Other:_____ 
 
18. How brings the child to their check-ups? 
o Mum 
o Dad 
o Other:_______ (specify) 
 
19. Are there any laws/public rights for parents to get extra time off work to take their 
children to check ups?  
o Yes 
o No 
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!20. Are parents with chronic ill children allowed to take additional days off compared 
to the general population?  
o Yes (________number of additional days) 
o No 
 
21. Are there national guidelines for the management of children with T1D and T2D? 
o Yes 
o No 
 
 
Patient organizations 
 
 
22. Are there any national organizations for patients with diabetes? 
o Yes 
o For children? 
o For children and adults? 
o For adults only? 
o No 
 
23. Are there any local organizations for patients with T1D? 
o Yes 
o For children? 
o For children and adults? 
o For adults only? 
o No 
 
Comment:  
 
 
24. What do the patient organizations offer the children and their parents? 
o Websites  
o Telephone 
o Courses 
o Information meetings 
o Holiday offers 
o Other:_________ 
 
Register for diabetes 
 
25. Is there a national diabetes register? 
o Yes, for children 
o Yes, for adults 
o Yes, for adults and children 
o No  
 
26. If yes, what data is registered? 
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Complications 
 
27. What is the incidence of acute diabetes complications among children under 15 
years of age? 
o Diabetic ketoacidosis (with hospitalization)  
o Grave hypoglycemia (unconscious with or without convulsions)  
 
28. What is the incidence of late diabetes complications among children under 15 
years of age? (estimated percentage) 
o Retinopathy 
o Nefropathy 
o Nevropathy 
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Country: 
Region/county/state: 
Local treatmentcenter (name and type): 
Date: 
Informant: name/occupation  
Interview by: 
 
PART 2 
 
Hospitalizations and number of hospital beds 
 
29. How many children <15 years with diabetes are admitted to hospital annually in 
the following wards (The total number of hospitalizations including 
rehospitalization) 
o Pediatric ward  
o Adolescens ward 
o Internal medical ward 
 
 
30. To what age are the children managed in the pediatric wards?_____ 
 
31. If there is an adolescent department, when do the children start attending and how 
long can they attend there? 
 
32. What is the maximum number of beds in the ward? _________ 
 
33. How often has the ward been full during the last 6 months? (regardless of the 
reason for the hospitalisation) 
 
34. How many children with diabetes are followed up at the local hospital today? 
 
35. How is the gender distribution among the children that are followed up at the local 
hospital? 
 
36. Who takes over the responsibility for the treatment and follow-up after the 
diagnosis of diabetes? 
o Specialist __________ (which type) 
o General practitioner (GP) 
o Other :________ 
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!Diagnostics 
 
37. Who usually make the diagnosis? 
o General practice 
o Specialised health service 
o Nurse 
o Other:_________ 
 
38.  What is the average age at diagnosis? 
 
39. What are the classical symptoms that make the patient and his or her parents 
contact a doctor? 
 
40.  Which diagnostic criteria have to be fulfilled to make the diagnose of diabetes? 
 
o International guidelines; ISPAD (Blood glucose) 
o Other guidelines:__________________ 
 
41. Where are recently diagnosed juvenile diabetics treated the first time? 
o  Out-patients clinic 
o Hospital ward with beds 
 
42. If the patient is admitted to hospital, what is the average length of stay? 
 
43. Which diagnostic criteria do you use for DKA? 
o Hyperglycemia 
o Standard Bicarbonate (< 15 mmol) 
o pH (< 7,3) 
o Urine ketons 
 
44. What proportion of children has DKA at diagnosis? 
 
 
Treatment and follow up 
 
45. Who participates in the treatment and follow up of children with diabetes? 
o Nurse 
o Doctor 
o School nurse 
o Social worker 
o Nutritionist  
o Psychologist 
o Other:___________ 
o Multidisciplinary team 
 
46. Does the child with diabetes have one particular contact person? If yes, specify: 
o Yes:___________ 
o No 
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!47. When the diagnosis is made who is responsible for the follow-up? 
o Specialist (doctor / diabetologist) 
o Hospital doctor 
o Nurse 
o General practitioner  
o Other:_________ 
 
48.  Who are educated (at the time of the diagnosis, and after discharge)? 
o The child 
o Parents 
o School  
o School nurse 
o Nursery 
o Activity leaders/coaches 
o Others:___________ 
o No one 
 
49. Does the hospital have access to interpreters when they have patients that do not 
speak/understand English? 
 
50. How is the education organized? 
o Training in groups 
o Individual training 
o A combination of both 
 
51. When is a new education organized? (re-education) 
 
52.  Is carbohydrate counting used systematically when calculating the insulin bolus 
in relation to food? 
 
 
53. How is the education organized? 
o Training in groups 
o Individual training 
o A combination of a and 
 
Comment: 
 
 
 
54. How much do parents participate in the treatment and follow up? 
 
55. Do the adolescents get contraceptive counseling? 
o Yes (comment;)_____________ 
o No 
 
56. Have you experienced unintended pregnancies in this group of patients? 
o Yes (how many? what are the characteristics of these patients; ethnicity, 
socioeconomic status etc?) 
o No 
59
! 
57. What types of treatment/treatment regimens are available for children with 
diabetes at the local hospital? 
o Syringes 
o Needles 
o Insulin pen 
o Insulin pump 
o Continuous Subcutaneous Glucose Monitoring  
o Others:_______________ 
o None 
 
58. How many patients use multi injection (insulin > 3 times a day) therapy? 
 
59. What proportion of the patients (in number and percentage) follow the different 
treatment regimens listed 
o Insulin pump: 
o Others: 
o None:? 
 
60. Among the children under multi injection therapy what type of insulin 
preparations are used? (%) 
o Premixed insulin preparations  
o Intermediate-acting insulin + rapid-acting insulin 
o Analogues 
o Which combinations: ____________ 
o Are there any different strategies for insulin therapy concerning the 
child´s age? 
 
 
 
61. Who does the patient and his or her parents contact if the child is acute ill? 
o Specialist  
o Contact person 
o GP 
o Emergency room 
o Other:__________ 
 
Treatment goals 
 
62. Are the ISPAD treatment goals adhered to? 
o Yes 
o No  
o If no, which guidelines are used______________ 
 
63.  What are the treatment goals 
o HbA1c < 7,5 % 
o Other:________ 
 
 
60
!64. What proportions (%) of patients achieve the treatment goals? 
 
65. How often do the children attend diabetes health check 
ups?____________________ 
 
66. What proportions (%) of the patients attend their appointment? 
 
 
o Most patients 
o 50 % 
o Only a few 
 
 
67. Who does not attend? Why? What are the characteristics of these patients? 
 
68. Is there a screening program for autoimmune diseases? 
o Yes 
o No  
 
69. If yes, witch diseases are included in the screening 
o Celiac disease 
o Hypothyroidism / hyperthyroidism 
o Others:___________________ 
 
70. If yes, how often is the screening performed 
o At each check up 
o Annually  
o Other:_____________________ 
 
71. Are there any screening program concerning late diabetes complications among 
children with diabetes? 
o Yes 
o No 
 
 
72. If yes, what kind of late diabetes complications are included in the screening 
program among children with diabetes? And which methods are used in the 
screening 
o Retinopathy:___________________________________________ 
o Nephropathy;____________________________________________ 
o Neuropathy:__________________________________________ 
o Angiopathy:__________________________________ 
o Others:__________________________ 
 
73. If yes on question 70, how often is the screening performed 
o At every check up: 
o Annually: 
o Other: _______ 
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!Quality of life and mental health: 
 
74. What assistance do the children with diabetes and their parents  receive in relation 
to: 
 
o School 
o Hobbies   
o Sports 
 
75. Are there social activities arranged for the children and their parents?  
 
76. What kind of social activities are arranged? And who organises them? 
 
77. Have you conducted/do you conduct research on the quality of life in the children 
with diabetes? 
 
o Yes 
! If yes, can you elaborate 
 
o No 
 
78.  Are intoxicants a problem among children with T1D? 
o Yes 
o What kind of intoxicant? 
o What are the characteristics of these patients (gender, ethnicity, 
socioeconomic status etc) 
o No 
 
Comment: 
 
Complications 
 
79. What is the incidence (percentage) of acute diabetes complications among 
children with T1D under the age of 15? 
o Diabetic ketoacidosis 
o Hypoglycemic shock with unconsciousness and/or convulsions 
o Other:___________ 
 
80. What is the incidence (%) of long-term complications among children under the 
age of 15 years? And how old are they? 
o Retinopathy: 
How many have been treated with laser? 
o Nephropathy: 
o Neuropathy: 
o Hypertension  
How many get anti hypertension treatment? 
 
81. What is the incidence (%) of long-term complication among adults who got the 
diagnose of diabetes before they turned 15 years? 
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      The following must be discussed: 
o How old were the patients when they where diagnosed with diabetes? 
o How many years diabetes duration at onset of the late complication? 
 
o Retinopathy: 
o Nephropathy: 
o Neuropathy: 
 
 
82. Is overweight a problem among children with diabetes? 
o If yes: 
o Are there any differences between gender, ethnicity, socioeconomic 
background etc? 
o In which group is the prevalence of overweight highest? 
o What kind of prevention and treatment regimens does the hospital have? 
o Are the treatment regimens effective? 
o Do children with overweight in practice have significant more complications 
than children with normal weight? 
o Are there other problems related to overweight and diabetes? 
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